

## **Alberto Pappo, M.D.**

St. Jude Children's Research Hospital  
262 Danny Thomas Place  
Mail Stop 260  
Memphis, TN 38015  
(901) 595-6765  
[alberto.pappo@stjude.org](mailto:alberto.pappo@stjude.org)

---

### **Current Position at St Jude**

Director, Division of Solid Tumor Malignancies St. Jude Children's Research Hospital Memphis, TN 38015	2010 - Present
--	----------------

### **Education and Training**

M.D., Medical School: Universidad Anahuac; Mexico City	1978-1984
Residency, University of Texas Health Science Center, San Antonio, TX	1985-1988
Fellowship, Children's Medical Center of Dallas and University of TX Southwestern Medical Center at Dallas, Dallas, Texas	1988-1991

### **Professional Career**

Pediatric Residency The University of Texas Health Science Center at San Antonio San Antonio, TX	1985-1988
Pediatric Hematology Oncology Fellowship Children's Medical Center of Dallas and the University of Texas Southwestern Medical Center at Dallas Dallas, TX	1988-1991
Assistant Professor Department of Pediatrics University of Tennessee, College of Medicine Memphis, TN	1991-1997
Assistant Member Department of Hematology-Oncology St. Jude Children's Research Hospital Memphis, TN	1991-1997
Associate Professor Department of Pediatrics University of Tennessee, College of Medicine Memphis, TN	1997 -2001
Associate Member Department of Hematology-Oncology St. Jude Children's Research Hospital Memphis, TN	1997 -2001

Professor of Pediatrics The Hospital for Sick Children Toronto ON, Canada	2001-2006
Head Solid Tumor Section Department of Haematology/Oncology The Hospital for Sick Children Toronto ON, Canada	2001-2006
Professor of Pediatrics Baylor College of Medicine Head-Division of Solid Tumors Texas Children's Cancer Center Houston, TX	2006-2009
Member Department of Oncology Division of Solid Tumor St. Jude Children's Research Hospital Memphis, TN 38015	2010-Present

### **Certifications and Licensure**

American Board of Pediatrics # 40972	06/1989	
American Board of Pediatric Hematology-Oncology	08/1992	American
Board of Pediatric Hematology-Oncology (recertified)	03/2007	
ECFMG	07/1983	
Florida Medical License	09/1987	
Texas Medical License	12/1989	
Tennessee Medical License	05/1991	
DEA	08/2006	
College of Physicians and Surgeons of Ontario 77153	2001-2006	

### **Professional Memberships**

ASCO	1991-present
PDQ Editorial Member	2005-present
NCCN St Jude Representative and Member Soft Tissue Sarcoma and AYA Panels	2012-present

### **Editorial Board Appointments**

Sarcoma  
Journal of Clinical Oncology  
NCCN AYA task force  
NCCN Soft tissue sarcoma task force  
ASCO.net  
Up-to-date  
PDQ

### **Grant Review / Study Activities**

Reviewer grants for Gateway for Cancer Research

Reviewer grants for Cookies for Kids  
 Reviewer grants for Sarcoma Foundation of America  
 Reviewer grants V Foundation

## Honors and Awards

American Cancer Society Clinical Fellowship	1989-1990
St. Jude Pediatric Faculty Teaching Award. Presented by the Pediatric and Medicine/Pediatric house staff. University of Tennessee	1992-1993
St. Jude Pediatric Faculty Teaching Award. Presented by the Pediatric and Medicine/Pediatric house staff. University of Tennessee	1996-1997
Hospital for Sick Children: The Alvin Zipursky Teaching Award in recognition for outstanding contribution to medical education and mentorship	2004-2005
Texas Children's Hospital Fellow's Excellence in Education Award	2007-2008
Distinguished Service Award Children's Oncology Group	2008
National Institutes of Health Award of Merit for the PDQ Pediatric Editorial Board	2010

## Institutional and Committee Assignments

### ***Institutional Service (committees, program initiatives, teaching, etc)***

Member Cancer Center Advisory Committee Member  
 PCGP Steering Committee  
 Member Pharmacy Oversight Committee  
 Member Faculty Appointments and Promotions Committee  
 Member Executive Committee  
 Director of the Organizer of the CTRSTC (Clinical Translational Research in Solid Tumor Conference)  
 Organizer biannual pediatric and adolescent melanoma clinic  
 Member Graduate School Leadership Team  
 Member advance practice council meeting  
 Promesa y Esperanza lunch/fundraiser 1/20/2018  
 Member biostatistics chair search committee  
 Chair NPTP task force  
 Member clinical office working group committee  
 Lead solid tumor program working group on imaging strategies

### ***Committees***

Member Soft Tissue Sarcoma Committee Children's Oncology Group	1996-present
Member Rare Tumor Committee Children's Oncology Group	2000-present
Member Nominating Committee Children's Oncology Group	2005-2007
Member Pediatric NCI PDQ Pediatric Board	1999-present
Chair Certification and Continuing Education Committee	
American Society of Pediatric Hematology Oncology (ASPHO)	2008-2010
Chair Data Safety Monitoring Board for Phase III Studies Children's Oncology Group	2010-2013
Vice-Chair Data Safety Monitoring Board for Phase III Studies Children's Oncology Group	2013-present
Vice Chair NCCN AYA Task Force	2013-present
Member NCCN sarcoma Task Force	2013-present
Chair Pediatric Oncology Drug Advisory Committee FDA	2014-present

## Professional Administrative Services

Treating rare cancers in children: the importance of evidence	ASCO 2012
Pediatric melanoma the whole (genome) story	ASCO 2014

Ewing sarcoma: Is there a role for high dose chemotherapy  
Rare tumors: Improving outcomes in the modern era

ASCO 2016  
ASCO 2015

## Formal Education/Teaching Activities

Head solid tumor section. Hospital for SICKKIDS	2001-2006
Head solid tumor section Texas Children's Hospital Baylor College of Medicine	2006-2009
Head Division of Solid Tumors St Jude Children's Research Hospital	2010-present
Co-leader Developmental Biology and solid tumor program.- St Jude Children's Research Hospital	2010-present

## Grant Awards

### A. Active Grants:

5 P30CA021765-38 Bahrami Dev F (PI-Bahrami) NCI (Co-investigator-Pappo) Molecular Analysis of Melanocytic Neoplasms (CCSG Carryforward Funds YR38)	6/9/2014 - 2/28/2019 \$22,188.00
5 P30CA021765-38 MAJOR PROG LE (Roberts) NCI (Co-investigator-Pappo) Cancer Center Support Grant (CCSG) MPL-YR 38	6/9/2014 - 2/28/2019 \$210,735.00
MEKPEM (PI-Pappo) MERCK & CO., INC. Pembrolizumab in advanced melanoma and solid tumors	01/30/2015 – 01/29/2020 \$536,182
Novartis CLDK378X2103 (PI-Pappo) Novartis Pharmaceuticals Phase I Trial Malignancies with ALK alteration LDKALK	07/01/2016 – 12/31/2018 \$7,800
LOXO-TRK-15003 (PI-Pappo) Loxo Pharmaceuticals Phase I study of LOXO101 in advanced solid tumors	04/13/2016 – 04/12/2021 \$15,779
KHCC-Fellowship (PI-Pappo) KING HUSSEIN CANCER CENTER (KHCC) King Hussein Cancer Center-Fellowship	7/31/2017 - 7/30/2018 \$47,440.00

### B. Pending Grants:

None

### C. Completed Grants:

160230040 IRUSIRE0181 Phase I ZD1839 and Oral Irinotecan in Children with Refractory Solid Tumors	07/01/2008 – 11/30/2014 \$113,960.00
5 P30 CA021765-33 MPL COG Chair's Developmental Fund (Translational Research) Award Program: Epigenetic Status of KCNQ10T1 in Sporadic Non-Wilms' Tumor Embryonal Tumors Associated with Molecular Alterations of Chromosome 11p15.	03-01-11 – 02-28-12 \$48,834.00

181200025 SARC (YR 2) SARC Funding Agreement for Clinical Trial SARC-012	08/01/2013 – 07/31/2015 \$8,667
160363010 CA 184178 (YR 1) MELBMS Ipilimumab Phase I Trial in Pediatric Melanoma	11/01/2012 – 05/31/2016 \$24,667
Protocol No. CLDK378X2103 LDKALK Phase I Trial Malignancies with ALK alteration	07/15/2013 – 06/30/2016 \$215,588
MELBMS CA184178 Bristol Myers Phase II Study of Ipilimumab in Children & Adolescents (12 to < 18 years) w/Previously Treated/Untreated, Unresectable Stage III or Stage IV Malignant Melanoma (BMS Clinical Protocol CA184178) MELBMS	07/01/2016 – 05/31/2017 \$6,600

## Clinical Trials Involvement

- A phase II trial of Ifosfamide in previously untreated children and adolescents with unresectable rhabdomyosarcoma.  
1993. (St Jude)
- A Phase II trial of high-dose methotrexate in previously untreated children and adolescents with high-risk unresectable or metastatic rhabdomyosarcoma.  
1997 (St Jude)
- Phase I targeted systemic exposure study of Paclitaxel in children with refractory acute leukemias.  
1999 (St Jude)
- Phase II trial of neoadjuvant vincristine, ifosfamide, and doxorubicin with granulocyte colony-stimulating factor support in children and adolescents with advanced stage nonrhabdomyosarcomatous soft tissue sarcomas.  
2005 (COG)
- Concomitant administration of vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide for high risk sarcoma.  
2006 (St Jude)
- The feasibility of adjuvant interferon alpha-2b in children with high-risk melanoma.  
2005 (St Jude)
- Two consecutive phase II window trials of irinotecan alone or in combination with vincristine for the treatment of metastatic rhabdomyosarcoma.  
2007 (COG)
- R1507, a Monoclonal Antibody to the Insulin-Like Growth Factor 1 Receptor in Patients With Recurrent or Refractory Ewing Sarcoma Family of Tumors:  
2011 (International Roche Trial)
- A Phase II Trial of R1507, a Monoclonal Antibody to the Insulin-Like Growth Factor-1 Receptor (IGF-1R) in Patients with Recurrent or Refractory Rhabdomyosarcoma, Osteosarcoma, Synovial Sarcoma, and Other Soft Tissue Sarcomas  
2014 (International Roche Trial)
- Shorter Duration Therapy using Vincristine, Dactinomycin, and Lower-Dose Cyclophosphamide with or without Radiotherapy for Patients with Newly Diagnosed Low-Risk Rhabdomyosarcoma:  
2014 (Co-PI) (COG)
- Reduction of cyclophosphamide dose for patients with subset 2 low-risk rhabdomyosarcoma is associated with an increased risk of recurrence:  
2017 (Co-PI) (COG)

Phase II study of ipilimumab in adolescents with unresectable stage III or IV malignant melanoma.  
2017 (International BMS Trial)

## Publication Record

### A. Peer Reviewed Publications

#### Original Research Articles:

**Pappo AS**, Buchanan GR, Johnson A: Septic arthritis in children with hemophilia. *Am J Dis Child* 143:1226-1228, 1989.

**Pappo A**, Dubowy R, Ravindranath Y, Alvarado C, Rao S, Whitehead VM, Vega R, Kamen B, Vietti T: Phase II trial of trimetrexate in the treatment of recurrent acute lymphoblastic leukemia: A Pediatric Oncology Group study. *J Natl Cancer Inst* 82:1641-1643, 1990.

Carrol A, Civin C, Schneider N, Dahl G, **Pappo A**, Bowman P, Emani A, Gross S, Alvarado C, Phillips C, Krischer J, Crist W, Head D, Gresik M, Ravindranath Y, Weinstein H: The t(1;22) (p13;q13) is non-random and restricted to infants with acute megakaryoblastic leukemia: A Pediatric Oncology Group study. *Blood* 78:748-752, 1991.

Chan WC, Carroll A, Alvarado CS, Phillips S, Gonzales-Crussi F, Kurczynski E, **Pappo A**, Emani A, Bowman P, Head DR. Acute megakaryoblastic leukemia in infants with t(1;22) (p13;q13) abnormality. *Am J Clin Pathol* 98:214221, 1992.

**Pappo AS**, Fields B, Buchanan GR: Etiology of red blood cell macrocytosis during childhood: Impact of new diseases and therapies. *Pediatrics* 89:1063-1067, 1992.

**Pappo A**, Vats T, Williams TE, Bernstein M, Kamen B: A phase I trial of trimetrexate in pediatric solid tumors: A Pediatric Oncology Study. *Med Pediatr Oncol* 21:280-282, 1993.

**Pappo A**, Etcubanas E, Santana VM, Rao BN, Kun LE, Fontanesi J, Roberson PK, Bowman LC, Crist WM, Shapiro DN: A phase II trial of Ifosfamide in previously untreated children and adolescents with unresectable rhabdomyosarcoma. *Cancer* 71:2119-2125, 1993.

**Pappo AS**, Douglass EC, Meyer WH, Marina N, Parham DM. Use of HBA 71 an anti- 2-microglobulin to distinguish peripheral neuroepithelioma from neuroblastoma. *Hum Pathol* 24:880-885, 1993.

**Pappo AS**, Crist WM, Kuttesch J, Rowe S, Ashmun RA, Maurer HM, Newton WA, Asmar L, Luo X, Shapiro DN. Tumor cell DNA content predicts outcome in children and adolescents with clinical group III embryonal rhabdomyosarcoma. *J Clin Oncol* 11:1901-1905, 1993.

Mustafa MM, **Pappo A**, Cash J, Winick NJ, Buchanan GR. Aerosolized pentamidine for the prevention of pneumocystis carinii pneumonia in cancer patients intolerant or allergic to trimethoprim/sulfamethoxazole. *J Clin Oncol* 12:258-261, 1994.

Rogers DA, Lobe TE, Rao BN, Fleming ID, Schropp KP, Pratt CB, **Pappo AS**. Breast malignancy in children. *J Pediatr Surg* 29:48-51, 1994.

**Pappo AS**, Fontanesi J, Luo X, Rao BN, Parham DM, Hurwitz C, Avery L, Pratt CB. Synovial sarcoma in children and adolescents. The St. Jude Children's Research Hospital Experience. *J Clin Oncol* 12:2360-2366, 1994.

Gallego M, Carroll AJ, Gad SG, **Pappo A**, Head D, Behm F, Ravindranath Y, Raimondi SC. Variant (8;21) rearrangements in acute myeloblastic leukemia of childhood. *Cancer Genet Cytogenet* 75:139-144, 1994.

Marina NM, Shema SJ, Bowman LC, Rodman J, Douglass EC, Furman WL, **Pappo A**, Santana VM, Hudson M, Meyer WH, Pratt CB. Failure of granulocyte-macrophage colony-stimulating factor to reduce febrile neutropenia in children with recurrent solid tumors treated with ifosfamide, carboplatin, and etoposide chemotherapy. *Med Pediatr Oncol* 23:328-334, 1994.

Aquino VM, **Pappo A**, Buchanan GR, Tkaczewski I, Mustafa MM. The changing epidemiology of bacteremia in neutropenic children with cancer. *Pediatr Infect Dis J* 14:140-143, 1995.

Downing JR, Khanderkar A, Shurtleff SA, Head DR, Parham DM, Webber BL, **Pappo AS**, Hulshof MG, Conn WP, Shapiro DN. A multiplex RT-PCR assay for the differential diagnosis of alveolar rhabdomyosarcoma versus Ewing's sarcoma. *Am J Pathol* 146:626-634, 1995.

**Pappo AS**, Kuttesch JF, Kaste SC, Parham DM, Rao BN, Pratt CB. Malignant melanocytic lesions of unknown primary site in children and adolescents. *Med Pediatr Oncol* 24:315-320, 1995.

Regine WF, Fontanesi J, Kumar P, Ayers D, Bowman L, **Pappo A**, Coffey D, Avery L, Rao BN, Kun LE. Evaluation of local control for initially unresectable rhabdomyosarcoma with selective use of low-doses irradiation following induction chemotherapy with or without delayed surgery. *Int J Rad Oncol Biol Phys* 31:485-491, 1995.

Pratt CB, Bowman LC, Marina N, **Pappo A**, Relling MV, Avery L, Luo X, Meyer WH. A phase I study of sulofenur in refractory pediatric malignant solid tumors. *Invest New Drugs* 13:63-66, 1995.

**Pappo AS**. Rhabdomyosarcoma and other soft tissue sarcomas in children and adolescents. *Curr Opin Oncol* 7:361-366, 1995.

Sonnichsen DS, Liu Q, Schuetz EG, **Pappo A**, Rahman A, Harris JW, Relling MV. Variability in cytochrome P450 paclitaxel metabolism in vitro and in vivo. *J Pharm Exp Therap* 275:566-575, 1995.

Rogers DA, Rao BN, Meyer WH, **Pappo A**, Lobe TE, Fleming ID, Kauffman WM. Indications for hemiscrotectomy in the management of genitourinary tumors in children. *J Pediatr Surg* 30: 1437-1439, 1995.

DeCou JM, Rao BN, Parham DM, Lobe TE, Bowman L, **Pappo AS**, Fontanesi J. Malignant peripheral nerve sheath tumors: The St. Jude Children's Research Hospital experience. *Ann Surg Oncol* 2:524-529, 1995.

**Pappo AS**, Parham DM, Cain A, Luo X, Bowman LC, Furman WL, Rao BN, Pratt CB. Alveolar soft part sarcoma in children and adolescents: Clinical features and outcome 11 patients. *Med Pediatr Oncol* 26:81-84, 1996.

Kanwar VS, **Pappo AS**, Albuquerque MLC, Marina NM, Kauffman WM, Furman WL. Chemotherapy related venoocclusive disease of the liver. [Letter]. *Med Pediatr Oncol* 25:486, 1995.

Priest JR, Watterson J, Strong LC, Huff V, Woods WG, Byrd RG, Friend SH, Newsham I, Amylon MD, **Pappo A**, Mahoney DH, Langston C, Heyn R, Kohut G, Freyer DR, Bostrom B, Richardson MS, Barredo J, Dehner LP. Pleuropulmonary blastoma: A marker for familial disease. *J Pediatr* 128:220-224, 1996.

Kuttesch JF, Parham D, Luo X, Meyer W, Bowman L, Shapiro D, **Pappo A**, Crist W, Beck W, Houghton P. PGlycoprotein-mediated multidrug resistance may not be a primary mechanism of therapeutic failure in childhood rhabdomyosarcoma. *J Clin Oncol* 14:886-900, 1996.

Mustafa MM, Aquino VM, **Pappo A**, Tkaczewski I, Buchanan GR. A pilot study of outpatient management of febrile neutropenic children with cancer at low risk of bacteremia. *J Pediatr* 128:847-849, 1996.

Kaste SC, **Pappo AS**, Jenkins JJ, Pratt CB. Malignant melanoma in children: Imaging spectrum. *Pediatr Radiol* 26:800-805, 1996.

Fontanesi J, **Pappo AS**, Parham DM, Hurwitz CA, Rao BN, Luo X, Kun LE, Pratt CB. Role of irradiation in the management of synovial sarcoma: St. Jude Children's Research Hospital Experience. *Med Pediatr Oncol* 26:264-267, 1996.

Gross E, Rao BN, **Pappo A**, Bowman L, Shearer P, Kaste S, Greenwald C, Michalkiewicz E, Pratt C. Epithelioid sarcoma in children. *J Pediatr Surg* 31:1663-1665, 1996.

Gross E, Rao BN, **Pappo AS**, Michalkiewicz E, Hudson MM, Kaste SC, Greenwald CA, Pratt CB. Soft tissue sarcoma of the hand in children: Clinical outcome and management. *J Pediatr Surg* 32:698-702, 1997.

**Pappo AS**, Rao BN, Cain AS, Bodner S, Pratt CB. Dermatofibrosarcoma protuberans: The pediatric experience at St. Jude Children's Research Hospital. *Pediatr Hematol Oncol* 14:563-568, 1997.

Rodriguez-Galindo C, **Pappo AS**, Kaste SC, Jenkins JJ, Kun LE, Rao BN, Pratt CB. Brain metastasis in children with melanoma. *Cancer* 79:2440-2445, 1997.

**Pappo AS**, Bowman LC, Furman WL, Rao BN, Kun LE, Jenkins JJ, Crom WR, Luo X, Kaste SC, Avery L, Meyer WH, Shapiro DN, Crist WM. A Phase II trial of high-dose methotrexate in previously untreated children and adolescents with high-risk unresectable or metastatic rhabdomyosarcoma. *J Pediatr Hematol Oncol* 19:438-442, 1997.

Ortega JA, Donaldson SS, Percy Ivy S, **Pappo A**, Maurer HM. Venooclusive disease of the liver after chemotherapy with vincristine, actinomycin D, and cyclophosphamide for the treatment of rhabdomyosarcoma. *Cancer* 79:2435-2439, 1997.

Pratt CB, Meyer WH, Luo X, Cain AM, Kaste SC, **Pappo AS**, Rao BN, Fleming ID, Jenkins JJ. Second malignant neoplasms occurring in survivors of osteosarcoma. *Cancer* 80:960-965, 1997.

Walter AW, Shearer PD, **Pappo AS**, Greenwald CA, Rao BN, Bowman LC, Furman WL, Gajjar A, Jenkins JJ, Pratt CB. A pilot study of vincristine, ifosfamide, and doxorubicin in the treatment of pediatric non-rhabdomyosarcoma soft tissue sarcomas. *Med Pediatr Oncol* 30: 210-216, 1998.

Gross E, Rao BN, Bowman L, Michalkiewicz E, **Pappo A**, Santana V, Kaste S, Greenwald C, Pratt C. Outcome of treatment for pediatric sarcoma of the foot: A retrospective review over a 20-year period. *J Pediatr Surg* 32:1181-1184, 1997.

Pratt CB, Meyer WH, Rao BN, **Pappo AS**, Fleming ID, Luo X, Cain A, Kaste SC, Shearer PD, Jenkins JJ. Comparison of primary osteosarcoma of flat bones with secondary osteosarcoma of any site. *Cancer* 80:1171-1177, 1997.

Michalkiewicz EL, Rao BN, Gross E, Luo X, Bowman LC, **Pappo AS**, Kaste SC, Hudson MM, Greenwald CA, Jenkins JJ, Pratt CB. Complications of pelvic exenteration in children who have genitourinary rhabdomyosarcoma. *J Pediatr Surg* 9:1277-1282, 1997.

Thompson, Pratt C, Stewart C, Avery I, Bowman L, Zamboni W, **Pappo A**. Phase I study of DMP840 in pediatric patients with refractory solid tumors. *Inv New Drugs* 16:45-49, 1998.

**Pappo AS**, Rao BN, Jenkins JJ, Merchant TE, Poquette CA, Cain A, Pratt CB. Metastatic non-rhabdomyosarcomatous soft tissue sarcomas in children and adolescents: The St. Jude Children's Research Hospital Experience. *Med Pediatr Oncol* 33:76-82, 1999.

Pratt CB, **Pappo AS**, Geiser P, Salzberg A, Marcus R, Rao BN, Jenkins JJ, Maurer HM. A randomized trial of chemotherapy with vincristine, dactinomycin, cyclophosphamide, doxorubicin vs observation in pediatric patients with surgically resected non-rhabdomyosarcomatous soft tissue sarcomas: A Pediatric Oncology Group Study. *J Clin Oncol* 17:1219-1226, 1999.

Zamboni WC, Bowman LC, Tan M, Santana VM, Houghton PJ, Meyer WH, Pratt CB, Heideman RL, Gajjar AJ, **Pappo AS**, Stewart CF. Interpatient variability in bioavailability of the intravenous formulation of topotecan given orally in children with relapsed solid tumors. *Ca Chemother Pharm* 43: 454-460, 1999.

Furman WL, Stewart CF, Poquette CA, Pratt CB, Santana VM, Zamboni WC, Bowman LB, Ma MK, Hoffer F, Meyer WH, **Pappo AS**, Walter A, Houghton PJ. Direct translation of a protracted irinotecan schedule from xenograft model to Phase I trial in children. *J Clin Oncol* 17:1815-1824, 1999.

Woo MH, Relling MV, Sonnichsen DS, Rivera GK, Pratt CB, Pui CH, Evans WE, **Pappo AS**. Phase I targeted systemic exposure study of Paclitaxel in children with refractory acute leukemias. *Clin Cancer Res* 5:543-549, 1999.

Marina NM, **Pappo AS**, Parham DM, Cain AM, Rao BN, Poquette CA, Pratt CB, Greenwald C, Meyer WH.



Chemotherapy dose-intensification for pediatric patients with Ewing's family of tumors and desmoplastic small round cell tumor: A feasibility study at St. Jude Children's Research Hospital. *J Clin Oncol* 17:180-190, 1999.

Parasuraman S, Rao BN, Bodner SM, Cain A, Pratt CB, Merchant TE, **Pappo AS**. Clear cell sarcoma in children and young adults: The St. Jude Children's Research Hospital experience. *Pediatr Hematol/Oncol* 16:539-544, 1999.

Parasuraman S, Langston J, Rao BN, Poquette CA, Jenkins JJ, Merchant TE, Cain A, Pratt CB, **Pappo AS**. Brain metastases in pediatric Ewing's sarcoma and rhabdomyosarcoma: the St. Jude Children's Research Hospital experience. *J Pediatr Hematol Oncol* 21:370-377, 1999.

Blakely, ML, Spurbeck WW, **Pappo AS**, Pratt CB, Rodriguez-Galindo C, Santana VM, Merchant TE, Prichard M, Rao BN. The impact of resection on outcome in pediatric nonrhabdomyosarcoma soft tissue sarcoma. *J Pediatr Surg* 34:672-675, 1999.

**Pappo A**, Anderson J, Grier H, Wharam M, Breitfeld P, Hawkins D, Raney B, Womer R, Parham D, Qualman S, Crist W. Survival after relapse in children and adolescents with rhabdomyosarcoma: A report from the Intergroup Rhabdomyosarcoma Study Group. *J Clin Oncol* 17:3487-3493, 1999.

McCarville MB, Kaste SC, **Pappo AS**. Pictorial Essay: Soft-tissue malignancies in infancy. *AJR* 173:973-977, 1999.

Spunt SL, Poquette CA, Hurt YS, Cain AM, Rao BN, Merchant TE, Jenkins JJ, Santana VM, Pratt CB, **Pappo AS**. Prognostic factors for children and adolescents with surgically resected (Clinical Group I-II) non-rhabdomyosarcoma soft tissue sarcoma (NRSTS): An analysis of 121 patients treated at St. Jude Children's Research Hospital. *J Clin Oncol* 17:3697-3705, 1999.

Spunt SL, Pratt CB, Rao BN, Pritchard M, Jenkins JJ, Hill A, Cain AM, **Pappo AS**. Childhood carcinoid tumors: The St Jude Children's Research Hospital Experience. *J Pediatr Surg* 35:1281-1286, 2000.

Spunt SL, McCarville MB, Kun LE, Poquette CA, Cain AM, Brandao L, **Pappo AS**. Selective use of whole-lung irradiation for patients with Ewing's sarcoma family of tumors and pulmonary metastases at the time of diagnosis. *J Pediatr Hematol/Oncol* 23:93-98, 2001.

Rodriguez-Galindo C, Ramsey K, Jenkins JJ, Poquette CA, Kaste SC, Merchant TE, Rao BN, Pratt CB, **Pappo AS**. Hemangiopericytoma in children and infants. *Cancer* 88:198-204, 2000.

Merchant TE, Parsh N, Lezama del Valle P, Coffey DH, Rodriguez-Galindo C, Jenkins JJ, **Pappo A**, Neel MD, Rao BN. Brachytherapy for pediatric soft tissue sarcoma. *Int J Radiation Oncology Biol Phys* 46:427-432, 2000.

Merchant TE, Nguyen D, Walter AW, **Pappo AS**, Kun LE, Rao BN. Long-term results with radiation therapy for pediatric desmoid tumors. *Int J Radiation Oncology Biol Phys.* 47:1267-1271, 2000.

Hayes-Jordan A, Spunt SL, Poquette CA, Cain AM, Rao BN, **Pappo AS**, Shochat SJ. Nonrhabdomyosarcoma soft tissue sarcomas in children: Is age at diagnosis an important variable? *J Pediatr Surg* 35:948-954, 2000.

Kogut KA, Fleming M, **Pappo AS**, Schropp KP. Sentinel lymph node biopsy for melanoma in young children. *J Pediatr Surg* 35:965-966, 2000.

Spunt SL, Lobe TE, **Pappo AS**, Parham DM, Wharam MD, Arndt C, Anderson JR, Crist WM, Paidas C, Wiener, E, Andrassy RJ, Schwartz CL. Aggressive surgery is unwarranted in biliary tract rhabdomyosarcoma. *J Pediatr Surg* 35:309-316, 2000.

Chow E, Merchant TE, **Pappo A**, Jenkins JJ, Shah AB, Kun LE Cutaneous and subcutaneous Ewing's sarcoma: An indolent disease. *Int J Radiation Oncology Biol Phys* 46:433-438, 2000.

Rodriguez-Galindo C, Poquette C, Marina NM, Head DR, Meyer WH, **Pappo AS**. Hematologic abnormalities and acute myeloid leukemia in children and adolescents administered intensified chemotherapy for the Ewing's sarcoma family of tumors. *J Pediatr Hematol-Oncol* 22:321-329, 2000.

**Pappo AS**, Lyden E, Breneman J, Wiener E, Teot L, Meza J, Crist W, Vietti T. Up-front window trial of topotecan in previously untreated children and adolescents with metastatic rhabdomyosarcoma: An Intergroup Rhabdomyosarcoma study (IRSG). *J Clin Oncol* 19:213-219, 2001.

Athale UH, Shurtleff S, Jenkins JJ, Poquette CA, Tan M, Downing JR, **Pappo AS**. Use of Reverse Transcriptase Polymerase Chain Reaction for Diagnosis and Staging of Alveolar Rhabdomyosarcoma, Ewing's Sarcoma Family of Tumors, and Desmoplastic Small Round Cell Tumor. *J Pediatr Hematol-Oncol* 23:99-104, 2001.

Raney BR, Anderson JR, Barr FG, Donaldson SS, **Pappo AS**, Qualman SJ, Wiener ES, Maurer HM, Crist WM. Rhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life: a selective review of Intergroup Rhabdomyosarcoma Study Group (IRSG) experience and rationale for Intergroup Rhabdomyosarcoma Study V. *J Pediatr Hematol-Oncol*. 23:215-220, 2001.

Meyer WH, Pratt CB, Poquette CA, Rao BN, Parham DM, Marina NM, **Pappo AS**, Mahmoud HH, Jenkins JJ, Harper J, Neel M, Fletcher BD. Carboplatin/Ifosfamide Window Therapy for Osteosarcoma: Results of the St Jude Children's Research Hospital OS-91 Trial. *J Clin Oncol* 19:171-182, 2001.

Hawkins DS, Anderson JR, Paidas CN, Wharam MD, Qualman SJ, **Pappo AS**, Baker S, Crist WM. Improved Outcome for Patients With Middle Ear Rhabdomyosarcoma: A Children's Oncology Group Study. *J Clin Oncol* 19: 3073-3079, 2001.

Spunt SL, Anderson JR, Teot LA, Breneman JC, Meyer WH, **Pappo AS**. Routine brain imaging is unwarranted in asymptomatic patients with rhabdomyosarcoma arising outside the head and neck region that is metastatic at diagnosis. A report from the Intergroup Rhabdomyosarcoma Study group. *Cancer* 92:121-125, 2001.

Walterhouse D, **Pappo A**, Baker S, Parham D, Anderson J, Donaldson S, Paidas C, Womer R, Crist W. Rhabdomyosarcoma of the parotid region occurring in childhood and adolescence: A report of the Intergroup Rhabdomyosarcoma Study Group. *Cancer* 92:3135-3146, 2001.

Miller SL, Hoffer FA, Miller SL, Hoffer FA, Reddick WE, Wu S, Glass JO, Gronemeyer SA, Haliloglu M, Nikanorov A, Xiong X, **Pappo AS**. Tumor volume or dynamic contrast-enhanced MRI for prediction of clinical outcome of Ewing sarcoma family of tumors *Pediatr Radiol* 31:518-523, 2001.

Venkateswaran L, Rodriguez-Galindo C, Merchant TE, Poquette CA, Rao BN, **Pappo AS**. Primary Ewing tumor of the vertebrae: Clinical characteristics, prognostic factors and outcome. *Med Pediatr Oncol* 37:30-35, 2001.

Rodriguez-Galindo C, Hill DA, Onyekere O, Pin N, Rao BN, Hoffer FA, Kun LE, **Pappo AS**, Santana VM. Neonatal alveolar rhabdomyosarcoma with skin and brain metastases. *Cancer* 92:1613-1620, 2001.

Smith LM, Anderson JR, Qualman SJ, Crist WM, Paidas CN, Teot LA, **Pappo AS**, Link MP, Grier HE, Wiener ES, Breneman JC, Raney BR, Maurer HM, Donaldson SS. Which Patients With Microscopic Disease and Rhabdomyosarcoma Experience Relapse After Therapy? A Report From the Soft Tissue Sarcoma Committee of the Children's Oncology Group *J Clin Oncol* 19:4058-4064, 2001.

Wagner L, Neel Michael D, **Pappo AS**, Merchant TE, Poquette CA, Rao BN, Rodriguez-Galindo C. , Fractures in Pediatric Ewing Sarcoma *J Pediatr Hematol-Oncol* 23: 568-571, 2001.

Rodriguez-Galindo C, Billups CA, Kun LE, Rao BN, Pratt CB, Merchant TE, Santana VM, **Pappo AS**. Survival after recurrence of Ewing's tumors. The St. Jude Children's Research Hospital experience 1979-1999. *Cancer* 94:561-569, 2002.

Hill DA, Dehner LP, Gow KW, **Pappo AS**, Crawford D, Pflaumer SM, Furman WL, Hayes-Jordan AA, McDermott MB. Perianal rhabdomyosarcoma presenting as a perirectal abscess: A report of 11 cases. *J Pediatr Surg*. 37:576-581, 2002.

Smitley BE, **Pappo AS**, Hill DA. C-kit overexpression in pediatric solid tumors: A comparative immunohistochemical study. *J Surg Pathol* 26:486-492, 2002.

Rodriguez-Galindo C, Daw NC, Kaste SC, Meyer WH, Dome JS, **Pappo AS**, Rao BN, Pratt CB. Treatment of refractory osteosarcoma with fractionated cyclophosphamide and etoposide. *J Pediatr Hematol Oncol* 24:250-255, 2002.

Spunt SL, Hill DA, Motosue AM, Billups CA, Cain AM, Rao BN, Pratt CB, Merchant TE, **Pappo AS**. Clinical features and outcome of initially unresected nonmetastatic pediatric nonrhabdomyosarcoma soft tissue sarcoma. *J Clin Oncol* 20:3225-3235, 2002.

McCarville MB, Spunt SL, Skapek SX, **Pappo AS**. Synovial sarcoma in pediatric patients. *Am J Roentgenol* 179: 797801, 2002

**Pappo AS**, Meza JL, Donaldson SS, Wharam MD, Wiener ES, Qualman SJ, Maurer HM, Crist WM. Treatment of localized nonorbital, nonparameningeal head and neck rhabdomyosarcoma: Lessons learned from Intergroup Rhabdomyosarcoma Studies III and IV. *J Clin Oncol* 121:638-645, 2003.

Chui CH, Spunt SL, Liu T, **Pappo AS**, Davidoff AM, Rao BN, Shochat SJ. Is reexcision in pediatric nonrhabdomyosarcoma soft tissue sarcoma necessary after an initial unplanned resection? *J Pediatr Surg* 37: 1424-1429, 2002.

Breneman JC, Lyden E, **Pappo AS**, Link MP, Anderson JR, Parham DM, Qualman SJ, Wharam MD, Donaldson SS, Maurer HM, Meyer WH, Baker KS, Paidas CN, Crist WM. Prognostic factors and clinical outcome in children and adolescents with metastatic rhabdomyosarcoma: A report from the Intergroup Rhabdomyosarcoma Study IV. *J Clin Oncol*. 21:78-84, 2003.

Hill DA, Riedley SE, Patel AR, Shurtleff SA, Hyer J, Cain AM, Billups CA, Downing JR, **Pappo AS**. Real time polymerase chain reaction as an aid for the detection of SYT-SSX1 and SYT-SSX2 transcripts in fresh and archival pediatric synovial sarcoma specimens: Report of 25 cases from St Jude Children's Research Hospital. *Pediatr Dev Pathol* 6:24-34, 2002.

Foley MR, Moshfeghi DM, Wilson MW, Haik BG, **Pappo AS**, Hill DA. Orbital inflammatory syndromes with systemic involvement may mimic metastatic disease. *Ophthalmic Plastic and Reconstructive Surgery*. *Ophtal Plast Reconstr Surg* 19:324-327, 2003.

Ocku FM, Munsell M, Treuner J, Mattke A, **Pappo A**, Cain A, Ferrari A, Casanova M, Ozkan A, Raney B. Synovial sarcoma of childhood and adolescence: A multicenter, multivariate analysis of outcome. *J Clin Oncol* 21: 1602-1611, 2003.

Daw NC, Billups CA, **Pappo AS**, Jenkins JJ, Mahmoud HH, Krasin MJ, Rao BN. Malignant fibrous histiocytoma and other fibrohistiocytic tumors in pediatric patient. The St Jude Children's Research Hospital experience. *Cancer* 97:2839-2847, 2003.

Kasow KA, Handgretinger R, Krasin MJ, **Pappo AS**, Leung W. Possible allogeneic graft-versus-tumor effect in childhood melanoma. *J Pediatr Hematol Oncol* 25:982-986, 2003.

Williams BA, Williams KM, Doyle J, Stephens D, Greenberg M, Malkin D, **Pappo AS**. Metastatic rhabdomyosarcoma: a retrospective review of patients treated at the Hospital for Sick children between 1989 and 1999. *J Pediatr Hematol Oncol* 26:243-247, 2004.

Sung L, Anderson JR, Arndt C, Raney RB, Meyer WH, **Pappo AS**. Neurofibromatosis in children with rhabdomyosarcoma: A report from the Intergroup Rhabdomyosarcoma Study IV. *J Pediatr* 144:666-668, 2004.

Cypriano MS, Jenkins JJ, Pappo AS, Rao BN, Daw NC. Pediatric gastrointestinal stromal tumors and leiomyosarcoma. *Cancer* 101:39-50, 2004.

Sung L, Anderson JR, Donaldson SS, Spunt SL, Crist WM, **Pappo AS**. Late events occurring five years or more after successful therapy for childhood rhabdomyosarcoma: a report from the Soft Tissue sarcoma Committee of the Children's Oncology Group. *Eur J Cancer* 40:1878-1885, 2004.

Spunt SL, Walsh MF, Krasin MJ, Helton KJ, Billups CA, Cain AM, **Pappo AS**. Brain metastases of malignant germ cell tumors in children and adolescents. *Cancer* 101:620-626, 2004.

Rodriguez-Galindo C, Wofford M, Castleberry RP, Swanson GP, London WB, Fontanesi J, **Pappo AS**, Douglass EC. Preradiation chemotherapy with methotrexate, cisplatin, 5-Fluorouracil, and leucovorin for pediatric nasopharyngeal carcinoma: results of Pediatric Oncology Group (now Children's Oncology Group) study 9486. *Cancer* 103:850-857, 2005.

**Pappo AS**, Devidas M, Jenkins J, Rao B, Marcus R, Thomas P, Gebhardt M, Pratt C, Grier HE. Phase II trial of neoadjuvant vincristine, ifosfamide, and doxorubicin with granulocyte colony-stimulating factor support in children and adolescents with advanced stage nonrhabdomyosarcomatous soft tissue sarcomas: A Pediatric Oncology Group Study. *J Clin Oncol* 18:2005.

Navid F, Furman WL, Fleming M, Rao BN, Kovach S, Billups CA, Cain AM, Amonette R, Jenkins JJ, **Pappo AS**. The feasibility of adjuvant interferon alpha-2b in children with high-risk melanoma. *Cancer* 103:780-787, 2005.

Price VE, Zielenska M, Chilton-MacNeill S, Smith C, **Pappo AS**. Clinical and molecular characteristics of pediatric gastrointestinal stromal tumors (GISTs). *Pediatr Blood Cancer* 45:20-24, 2005.

Chui CH, Billups CA, **Pappo AS**, Rao BN, Punt SL. Predictors of outcome in children and adolescents with rhabdomyosarcoma of the trunk-the St Jude Children's Research Hospital experience. *J Pediatr Surg* 40:1691-1695, 2005.

Navid F, Santana VM, Billups CA, Merchant TE, Furman WL, Spunt SL, Cain AM, Rao BN, Hale GA, **Pappo AS**. Concomitant administration of vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide for high risk sarcoma. *Cancer* 106:1846-1856, 2006.

Cantos MF, Gerstle JT, Irwin MS, **Pappo A**, Farley S, Cheang T, Kim PC. Surgical challenges associated with intensive treatment protocols for high-risk neuroblastoma. *J Pediatr Surg* 41:960-965, 2006.

Lager JJ, Lyden ER, Anderson JR, **Pappo AS**, Meyer WH. Pooled analysis of phase II window studies in children with contemporary high-risk metastatic Rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. *J Clin Oncol* 24:3415-3422, 2006.

Ramphal R, **Pappo A**, Zielenska M, Grant R, Ngan BY. Pediatric renal cell carcinoma: clinical, pathologic, and molecular abnormalities associated with the members of the mit transcription factor family. *Am J Clin Pathol* 126, 2006.

Shah NC, Gerstle T, Stuart M, Winter C, **Pappo A**. Use of sentinel lymph node biopsy and high-dose interferon in pediatric patients with high-risk melanoma: The Hospital for Sick Children experience. *J Pediatr Hematol Oncol* 28:496-500, 2006.

Meza JL, Anderson J, **Pappo AS**, Meyer WH. Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on Intergroup Rhabdomyosarcoma Studies III and IB: the Children's Oncology Group. *J Clin Oncol* 24:3844-3851, 2006.

Pappo AS, Lyden E, Breitfeld P, Donaldson SS, Wiener E, Parham D, Crews KR, Houghton P, Meyer WH. Two consecutive phase II window trials of irinotecan alone or in combination with vincristine for the treatment of metastatic rhabdomyosarcoma: The Children's Oncology Group. *J Clin Oncol* 25:362-369, 2007.

Al-Faris N, Al Harbi T, Goia C, **Pappo A**, Doyle J, Gassas A. Does consolidation with autologous stem cell transplantation improve the outcome of children with metastatic or relapse Ewing sarcoma? *Pediatr Blood Cancer* 49: 190-195, 2007.

Bond M, Bernstein ML, **Pappo A**, Schultz KR, Krailo M, Blaney SM, Adamson PC. A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: A Children's Oncology Group study *Pediatr Blood Cancer* Jan 29 2007.

Demetri GD, Benjamin RS, Blanke CD, Blay JY, Sacali P, Choi H, Corless CL, Debiec-Rychter M, DeMatteo RP,

Ettinger DS, Fisher GA, Fletcher C, Gronchi A, Hohenberger P, Hughes M, Joensuu H, Judson I, LeCesne A, Mako RG, Morse M, **Pappo AS**, Pisters P, Raut CP, Reichardt P, Tyler DS, Van den Abbeele AD, von Mehren M, Wayne JD, Zalberg J. NCCN task force report: Optimal management of patients with gastrointestinal stromal tumor (GIST) – Update of the NCCN clinical practice guidelines. *J Natl Compr Canc Net.* 5: Suppl 2 S1-S29, 2007.

Raney B, Chintagumpala M, Anderson J, **Pappo A**, Qualman S, Wharam M, Wiener E, Meyer W. Results of treatment of patients with superficial facial rhabdomyosarcomas on protocols of the Intergroup Rhabdomyosarcoma Study Group (IRSG), 1984-1997. *Pediatr Blood and Cancer.* 50:958-964, 2008. **PMCID: PMC3357210**

Wagner LM, Crews KR, Stewart CF, Rodriguez-Galindo C, McNall-Knapp RY, **Pappo AS**, Furman WL. Reducing irinotecan associated diarrhea in children. *Pediatr Blood and Cancer* 50:201-207, 2008.

Qualman S, Lynch J, Bridge J, Parham D, Teot L, Meyer W, **Pappo A**. Prevalence and clinical impact of anaplasia in childhood rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. *Cancer.* 2008 Dec 1;113(11):3242-7. Erratum in: *Cancer.* 2009 Jun 15;115(12):2806. **PMCID: PMC2727712**

Paulino AC, **Pappo A**. Alveolar rhabdomyosarcoma of the extremity and nodal metastases: Is the in-transit lymphatic system at risk. *Pediatr Blood and Cancer* 53:1332-3, 2009.

Katzenstein H, Chang K, Krailo M, Chen Z, Finegold M, Rowland J, Reynolds M, **Pappo A**, London W, Malogolowkin M. Amifostine does not prevent platinum-induced hearing loss associated with the treatment of children with hepatoblastoma: A report of the Intergroup Hepatoblastoma Study P9645 as a part of the Children's Oncology Group. *Cancer* 115:5828-35, 2009. **PMCID: PMC2795100**

Gupta AA, **Pappo A**, Saunders N, Hopyan S, Ferguson P, Wunder J, O'Sullivan B, Catton C, Greenberg M, Blackstein M. Clinical outcome of children and adults with localized Ewing sarcoma: impact of chemotherapy dose and timing of local therapy. *Cancer.* 2010 Jul 1;116 (13):3189-94.

Somers GR, Chilton-MacNeill S, Zheng K, Stuart M, **Pappo A**, Zielenska M, Thorner PS. Increased detection of metastatic melanoma in pediatric sentinel lymph node biopsies using RT-PCR on paraffin-embedded tissue. *Appl Immunohistochem Mol Morphol.* 2010 Jul;18(4):365-70.

Rednam S, Hicks J, Levy M, **Pappo A**. Metastatic squamous cell carcinoma of the oropharynx in a child with a mutation in the Connexin 26 gene. *J Pediatr Hematol Oncol.* 2010 Sep 8.

**Pappo AS**, Krailo M, Chen Z, Rodriguez-Galindo C, Reaman G. Infrequent tumor initiative of the Children's Oncology Group: initial lessons learned and their impact on future plans. *J Clin Oncol.* 2010 Nov 20;28(33):5011-6. **PMCID: PMC3020699**

Ferrari A, Miceli R, Rey A, Oberlin O, Orbach D, Brennan B, Mariani L, Carli M, Bisogno G, Cecchetto G, Salvo GL, Casanova M, Vannosel MM, Kelseay A, Stevens MC, Devidas M, **Pappo AS**, Spunt SL. Non metastatic unresected pediatric non-rhabdomyosarcoma soft tissue sarcomas: Results of a pooled analysis from United States and European groups. *Eur J Cancer.* 2011 Mar;47(5):724-31. **PMCID: PMC3539303**

Janeway KA, Kim SY, Lodish M, Nosé V, Rustin P, Gaal J, Dahia PL, Liegl B, Ball ER, Raygada M, Lai AH, Kelly L, Hornick JL; NIH Pediatric and Wild-Type GIST Clinic, O'Sullivan M, de Krijger RR, Dinjens WN, Demetri GD, Antonescu CR, Fletcher JA, Helman L, Stratakis CA. Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations. *Proc Natl Acad Sci U S A.* 2011 Jan 4;108(1):314-8. **PMCID: PMC3017134**

Walterhouse DO, Meza JL, Breneman JC, Donaldson SS, Hayes-Jordan A. **Pappo AS**, Arndt C, Raney RB, Meyer WH, Hawkins DS. Local control and outcome in children with localized vaginal rhabdomyosarcoma: A report from the Soft Tissue Sarcoma committee of the Children's Oncology Group. *Pediatr Blood Cancer.* 2011 Jul 15;57(1):76-83. **PMCID: PMC3459820**

Baruchel S, **Pappo A**, Krailo M, Baker S, Wu B, Blaney S, Scott M, Adamson P. A Phase II trial of trabectedin in children and adolescents with recurrent rhabdomyosarcoma, Ewing sarcoma and non rhabdomyosarcoma soft tissue sarcomas. *Eur J Cancer* 48:579-585, 2012. **NIHMSID: NIHMS331839**

Gupta AA, Anderson JR, **Pappo AS**, Spunt SL, Dasgupta R, Indelicato DJ, Hawkins DS. Patterns of chemotherapy-induced toxicities in younger children and adolescents with rhabdomyosarcoma: A Report From the Children's Oncology Group Soft Tissue Sarcoma Committee. *Cancer* 118:1130-1137, 2012. **PMCID: PMC4008942**

**Pappo AS**, Patel SR, Crowley J, Reinke DK, Kuenkele KP, Chawla SP, Toner GC, Maki RG, Meyers PA, Chug R, Ganjoo KN, Schuetze SM, Juergens H, Leahy MG, Geoerger B, Benjamin RS, Helman LJ, Baker LH. R1507, a Monoclonal Antibody to the Insulin-Like Growth Factor 1 Receptor in Patients With Recurrent or Refractory Ewing Sarcoma Family of Tumors: Results of a Phase II Sarcoma Alliance for Research through Collaboration Study. *J Clin Oncol* 29:4541-47, 2011. **PMCID: PMC3236654**.

Cheung NV, Zhang J, Lu C, Parker M, Bahrami A, Tickoo S, Heguy A, **Pappo AS**, Federico S, Dalton J, Cheung I, Ding L, Fulton B, Wang J, Chen X, Becksfort J, Wu J, Billups CA, Ellison D, Mardis E, Wilson R, Downing J, Dyer M. Association of age at diagnosis and genetic mutations in patients with neuroblastoma. *JAMA* 307(10):1062-71, 2012. **PMCID: PMC3527076**

Wang WL, Nero C, **Pappo A**, Dina Lev DL, Lazar AJ, Lopez-Terrada DH. CTNNB1 Genotyping and APC Screening in Pediatric Desmoid Tumors: A Proposed Algorithm. *Pediatr Dev Pathol.* 15:361-367, 2012.

Pui CH, Pei D, **Pappo AS**, Howard SC, Cheng C, Sandlund JT, Furman WL, Ribeiro RC, Spunt SL, Rubnitz JE, Jeha S, Hudson MM, Kun LE, Merchant TE, Kocak M, Broniscer A, Metzger ML, Downing JR, Leung W, Evans WE, Gajjar A. Treatment Outcomes in Black and White Children With Cancer: Results From the SEER Database and St. Jude Children's Research Hospital, 1992 Through 2007. *J Clin Oncol.* 30:2005-2012, 2012. **PMCID: PMC3383176**

Pashankar FD, Rodriguez-Galindo C, **Pappo A**. Development of a Therapeutic Approach to Rare Cancers in Children: The Children's Oncology Group Experience. *J Pediatr Hematol Oncol.* 2012 May;34 Suppl 2:S37-8.

Wagner AJ, Goldberg JM, Dubois SG, Choy E, Rosen L, **Pappo A**, Geller J, Judson I, Hogg D, Senzer N, Davis IJ, Chai F, Waghorne C, Schwartz B, Demetri GD. Tivantinib (ARQ 197), a selective inhibitor of mesenchymal-epithelial transition factor, in patients with microphthalmia transcription factor-associated tumors: Results of a multicenter phase 2 trial. *Cancer.* 118:5894-5902, 2012.

Kaste SC, Brady SL, Yee B, McPherson VJ, Kaufman RA, Billups CA, Daw NC, **Pappo AS**. Is routine pelvic surveillance imaging necessary in patients with Wilms tumor? *Cancer.* 119:182-188, 2013. **PMCID: PMC3461105**  
**Pappo AS**, Armstrong GT, Liu W, Srivastava DK, McDonald A, Leisenring WM, Hammond S, Stovall M, Neglia JP, Robison, LL. Melanoma as a subsequent neoplasm in adult survivors of childhood cancer: A report from the childhood cancer survivor study. *Pediatr Blood Cancer.* 60:461-466, 2013. **PMCID: PMC3538914**

Coccia PF, Altman J, Bhatia S, Borinstein SC, Flynn J, George S, Goldsby R, Hayashi R, Huang MS, Johnson RH, Beaupin LK, Link MP, Oeffinger KC, Orr KM, **Pappo AS**, Reed D, Spraker HL, Thomas DA, von Mehren M, Wechsler DS, Whelan KF, Zebrack BJ, Sundar H, Shead DA. Adolescent and young adult oncology. *J Natl Compr Canc Netw.* 2012 Sep 1;10(9):1112-50. **PMCID: n/a. Not Peer Review.**

Yang JJ, Lim JY, Huang J, Bass J, Wu J, Wang C, Fang J, Stewart E, Harstead EH, E S, Robinson GW, Evans WE, **Pappo A**, Zuo J, Relling MV, Onar-Thomas A, Gajjar A, Stewart CF. The Role of Inherited TPMT and COMT Genetic Variation in Cisplatin-Induced Ototoxicity in Children with Cancer. *Clin Pharmacol Ther.* 94:252-259, 2013. **PMCID: PMC3883563**

Shuldiner AR, Relling MV, Peterson JF, Hicks JK, Freimuth RR, Sadee W, Pereira NL, Roden DM, Johnson JA, Klein TE; Pharmacogenomics Research Network Translational Pharmacogenetics Program Group, Shuldiner AR, Vesely M, Robinson SW, Ambulos N Jr, Stass SA, Kelemen MD, Brown LA, Pollin TI, Beitelshes AL, Zhao RY, Pakyz RE, Palmer K, Alestock T, O'Neill C, Maloney K, Branham A, Sewell D, Relling MV, Crews K, Hoffman J, Cross S, Haidar C, Baker D, Hicks JK, Bell G, Greeson F, Gaur A, Reiss U, Huettel A, Cheng C, Gajjar A, **Pappo A**, Howard S, Hudson M, Pui CH, Jeha S, Evans WE, Broeckel U, Altman RB, Gong L, Whirl-Carrillo M, Klein TE, Sadee W, Manickam K, Sweet KM, Embi PJ, Roden D, Peterson J, Denny J, Schildcrout J, Bowton E, Pulley J, Beller M, Mitchell J, Danciu I, Price L, Pereira NL, Weinshilboum R, Wang L, Johnson JA, Nelson D, Clare-Salzler M, Elsey A, Burkley B, Langaee T, Liu F, Nessler D, Dong HJ, Lesko L, Freimuth RR, Chute CG. Source Program in Personalized and Genomic Medicine and Department of Medicine. The Pharmacogenomics Research Network Translational Pharmacogenetics Program: overcoming challenges of real-world implementation. *Clin Pharmacol Ther.* 2013 Aug;94(2):207-10. **PMCID: PMC3720847**

Chen X, Stewart E, Shelat AA, Qu C, Bahrami A, Hatley M, Wu G, Bradley C, McEvoy J, **Pappo A**, Spunt S, Valentine MB, Valentine V, Krafcik F, Lang WH, Wierdl M, Tsurkan L, Tolleman V, Federico SM, Morton C, Lu C, Ding L, Easton J, Rusch M, Nagahawatte P, Wang J, Parker M, Wei L, Hedlund E, Finkelstein D, Edmonson M, Shurtleff S, Boggs K, Mulder H, Yergeau D, Skapek S, Hawkins DS, Ramirez N, Potter PM, Sandoval JA, Davidoff AM, Mardis ER, Wilson RK, Zhang J, Downing JR, Dyer MA, on behalf of the St. Jude Children's Research Hospital–Washington University Pediatric Cancer Genome Project. Targeting Oxidative Stress in Embryonal Rhabdomyosarcoma. *Cancer Cell*. Dec 9;24(6):710-24, 2013. **PMCID: PMC3904731**

Coccia PF, **Pappo AS**, Altman J, Bhatia S, Borinstein SC, Flynn J, Frazier AL, George S, Goldsby R, Hayashi R, Huang MS, Johnson RH, Beaupin LK, Link MP, Oeffinger KC, Orr KM, Reed D, Spraker HL, Thomas DA, von Mehren M, Wechsler DS, Whelan KF, Zebrack B, Shead DA, Sundar H. Adolescent and young adult oncology, version 2.2014. *J Natl Compr Canc Netw*. 2014 Jan 1;12(1):21-32

**Pappo A**, Patel S, Crowley J, Reinke D, Brownstein C, Chawla S, Vassal G, Benjamin R, Helman L, Baker L. "A Phase II Trial of R1507, a Monoclonal Antibody to the Insulin-Like Growth Factor-1 Receptor (IGF-1R) in Patients with Recurrent or Refractory Rhabdomyosarcoma, Osteosarcoma, Synovial Sarcoma, and Other Soft Tissue Sarcomas: Results of a Sarcoma Alliance for Research through Collaboration Study" *Cancer*. 2014 Aug 15;120(16):2448-56.

Chen X, Bahrami A, **Pappo A**, Easton J, Dalton J, Hedlund E, Ellison D, Shurtleff S, Wu G, Wei L, Parker M, Rusch M, Nagahawatti P, Wu J, Mao S, Boggs K, Mulder H, Yergeau D, Lu C, Ding L, Edmondson M, Qu C, Wang J, Li Y, Navid F, Daw N, Mardis E, Wilson RK, Downing J, Zhang J, Dyer MA. Recurrent Somatic Structural Variations Contribute to Tumorigenesis in Osteosarcoma. *Cell Rep*. 2014 Apr 10;7(1):104-12. **PMCID: PMC4096827**

von Mehren M, Randall RL, Benjamin RS, Boles S, Bui MM, Casper ES, Conrad EU 3rd, Delaney TF, Ganjoo KN, George S, Gonzalez RJ, Heslin MJ, Kane JM 3rd, Mayerson J, McGarry SV, Meyer C, O'Donnell RJ, Pappo AS, Paz IB, Pfeifer JD, Riedel RF, Schuetze S, Schupak KD, Schwartz HS, Van Tine BA, Wayne JD, Bergman MA, Sundar H. Soft tissue sarcoma, version 2.2014. *J Natl Compr Canc Netw*. 2014 Apr 1;12(4):473-83. **PMCID: PMC4096827**

Flaherty L, Othus M, Atkins MB, Tuthill R, Thompson J, Vetto J, Haluska F, **Pappo AS**, Sosman J, Redman B, Moon J, Ribas A, Kirkwood J, Sondak V. Southwest Oncology Group S0008: A Phase III trial of high-dose interferon alpha-2b versus cisplatin, vinblastine, DTIC plus IL-2 and interferon in patients with high risk melanoma-An intergroup study of Cancer and Leukemia group B, Children's Oncology Group, Eastern Cooperative oncology Group and Southwest Oncology Group. *J Clin Oncol*. 2014 Nov 20;32(33):3771-8. **PMCID: PMC4226807**

Walterhouse D, **Pappo AS**, Meza JL, Breneman JC, Hayes-Jordan AA, Parham D, Cripe T, Anderson JR, Meyer WH, Hawkins D. Shorter Duration Therapy using Vincristine, Dactinomycin, and Lower-Dose Cyclophosphamide with or without Radiotherapy for Patients with Newly Diagnosed Low-Risk Rhabdomyosarcoma: A Report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. *J Clin Oncol*. 32:3547-3552, 2014. **PMCID: PMC4209105**

von Mehren M, Randall RL, Benjamin RS, Boles S, Bui MM, Casper ES, Conrad EU 3rd, DeLaney TF, Ganjoo KN, George S, Gonzalez RJ, Heslin MJ, Kane JM 3rd, Mayerson J, McGarry SV, Meyer C, O'Donnell RJ, **Pappo AS**, Paz IB, Pfeifer JD, Riedel RF, Schuetze S, Schupak KD, Schwartz HS, Van Tine BA, Wayne JD, Bergman MA, Sundar H. Gastrointestinal stromal tumors, version 2014. *J Natl Compr Canc Netw*. 2014 Jun;12(6):853-62.

Pacak K, Chew EY, **Pappo AS**, Yang C, Lorenzo FR, Wilson MW, Aronow MB, Young JA, Popovic V, Zhuang Z. Ocular Manifestations of Hypoxia-Inducible Factor-2 $\alpha$  Paraganglioma-Somatostatinoma-Polycythemia Syndrome. *Ophthalmology* 2014 Nov;121(11):2291-3. **PMCID: PMC4253312**

Lu C, Zhang J, Nagahawatte P, Easton J, Lee S, Liu Z, Ding L, Wyczalkowski MA, Valentine M, Navid F, Mulder H, Tatevossian R, Dalton J, Davenport J, Yin Z, Edmonson M, Rusch M, Wu G, Li Y, Parker M, Hedlund E, Shurtleff S, Raimondi S, Bhavin V, Donald Y, Mardis ER, Wilson RK, Evans WE, Ellison DW, Pounds S, Dyer M, Downing JR, **Pappo AS**, Bahrami A. The genomic landscape of childhood and adolescent melanoma. *J Invest Dermatol* 135:816-823, 2015. **PMCID: PMC4340976**

Stewart E, Goshorn R, Bradley C, Griffiths LM, Benavente C, Twarog NR, Miller GM, Caufield W, Freeman BB,

Bahrami A, **Pappo A**, Wu J, Loh A, Karlstrom A, Calabrese C, Gordon B, Tsurkan L, Hatfield MJ, Potter PM, Snyder SE, Thiagarajan S, Shirinifard A, Sablauer A, Shelat AA, Dyer MA. Targeting the DNA repair pathway in Ewing sarcoma. *Cell Reports* 9:829-840, 2014. **PMCID: PMC4386669**

Interiano RB, Loh AH, Hinkle N, Wahid FN, Malkan AD, Bahrami A, Jenkins JJ, Mao S, Wu J, Proctor K, Santana VM, **Pappo AS**, Gold RE, Davidoff AM. Safety and diagnostic accuracy of tumor biopsies in children with cancer. *Cancer* 121:1098-1107, 2015. **PMCID: PMC4368446**

Federico SM, Brady SL, **Pappo AS**, Wu J, Mao S, McPherson VJ, Young A, Furman WL, Kaufman R, Kaste S. The role of computed tomography (CT) as a surveillance tool in children with high-risk neuroblastoma. *Pediatr Blood and Cancer*. 2015 Jun;62(6):976-81. **PMCID: PMC4694045**

Pinto EM, Chen X, Easton J, Finkelstein D, Liu Z, Pounds S, Rodriguez-Galindo C, Lund TC, Mardis ER, Wilson RK, Boggs K, Yergeau D, Cheng J, Mulder HL, Manne J, Jenkins J, Mastellaro MJ, Figueiredo BC, Dyer MA, **Pappo A**, Zhang J, Downing JR, Ribeiro RC, Zambetti GP. Genomic landscape of paediatric adrenocortical carcinoma. *Nat Commun*. 2015 Mar 6;6:6302. **PMCID: PMC4352712**

Hurley C, McCarville MB, Shulkin BL, Mao S, Wu J, Navid F, Daw NC, **Pappo AS**, Bishop MW. Comparison of 18 FFDG-PET-CT and bone scintigraphy for evaluation of osseous metastases in newly diagnosed and recurrent osteosarcoma *Pediatr Blood Cancer*. 2016 Aug;63(8):1381-6. **PMCID: PMC5082741**

Bahrami A, Barnhill R, Dummer R, Lee S, Dalton J, Wu J, **Pappo A**. TERT Promoter Mutations Predict Aggressive Clinical Behavior in Patients with Spitzoid Melanocytic Neoplasms. *Scientific reports*. 2015 Jun 10;5:11200. **PMCID: PMC4462090**

Topka S, Vijai J, Walsh MF, Jacobs L, Maria A, Villano D, Gaddam P, Wu G, McGee RB, Quinn E, Inaba H, Hartford C, Pui CH, **Pappo AS**, Edmonson M, Zhang M, Stephensky P, Steinherz P, Schrader K, Lincoln A, Busse J, Lipkin S, Goldgur Y, Harit M, Stadler ZK, Mullighan C, Weintraub M, Shimamura A, Zhang J, Downing JR, Nichols KE, Offit K. Germline ETV6 mutations confer susceptibility to acute lymphoblastic leukemia and thrombocytopenia PL0S genetics. 2015 Jun 23;11(6):e1005262. eCollection 2015 Jun. **PMCID: PMC4477877**

Bishop MW, Somerville JM, Bahrami A, Kaste SC, Interiano RB, Wu J, Mao S, Boop FA, Williams RF, **Pappo AS**, Samant S. Mesenchymal Chondrosarcoma in Children and Young Adults: A Single Institution Retrospective Review. *Sarcoma*. 2015;2015:608279. **PMCID: PMC4469840**

Stewart E, Federico S, Karlstrom A, Shelat A, Sablauer A, **Pappo A**, Dyer MA. The Childhood Solid Tumor Network: A new resource for the developmental biology and oncology research communities. *Dev Biol*. 2016 Mar 15;411(2):287-293. **PMCID: PMC4600003**

Lee S, Barnhill RL, Dummer R, Dalton J, Wu J, **Pappo A**, Bahrami A. TERT Promoter Mutations Are Predictive of Aggressive Clinical Behavior in Patients with Spitzoid Melanocytic Neoplasms. *Sci Rep*. 2015 Jun 10;5:11200. **PMCID: PMC4462090**

**Pappo AS**, Furman WL, Schultz KA, Ferrari A, Helman L, Krailo MD. Rare Tumors in Children: Progress Through Collaboration. *J Clin Oncol*. 2015 Sep 20;33(27):3047-54. **PMCID: PMC4979197**

Brinkman TM, Bass JK, Li Z, Ness KK, Gajjar A, **Pappo AS**, Armstrong GT, Merchant TE, Srivastava DK, Robison LL, Hudson MM, Gurney JG. Treatment-induced hearing loss and adult social outcomes in survivors of childhood CNS and non-CNS solid tumors: Results from the St. Jude Lifetime Cohort Study. *Cancer*. 2015 Nov 15;121(22):4053-61. **PMCID: PMC4635051**

Stewart E, Shelat A, Bradley C, Chen X, Federico S, Thiagarajan S, Shirinifard A, Bahrami A, **Pappo A**, Qu C, Finkelstein D, Sablauer A, Dyer MA. Development and characterization of a human orthotopic neuroblastoma xenograft. *Dev Biol*. 2015 Nov 15;407(2):344-55. **PMCID: PMC4995597**

Zhang J, Walsh MF, Wu G, Edmonson MN, Gruber TA, Easton J, Hedges D, Ma X, Zhou X, Yergeau DA, Wilkinson MR, Vadodaria B, Chen X, McGee RB, Hines-Dowell S, Nuccio R, Quinn E, Shurtleff SA, Rusch M, Patel A, Becksfort JB, Wang S, Weaver MS, Ding L, Mardis ER, Wilson RK, Gajjar A, Ellison DW, **Pappo AS**, Pui CH, Nichols KE, Downing JR. Germline Mutations in Predisposition Genes in Pediatric Cancer. *N Engl J Med*. 2015 Dec 10;373(24):2336-46. **PMCID: PMC4734119**



Fan Y, Lee S, Wu G, Easton J, Yergeau D, Dummer R, Vogel P, Kirkwood JM, Barnhill RL, **Pappo A**, Bahrami A. Telomerase Expression by Aberrant Methylation of the TERT Promoter in Melanoma Arising in Giant Congenital Nevi. *J Invest Dermatol*. 2016 Jan;136(1):339-42. **PMCID: PMC4731027**

Wu G, Barnhill RL, Lee S, Li Y, Shao Y, Easton J, Dalton J, Zhang J, **Pappo A**, Bahrami A. The landscape of fusion transcripts in spitzoid melanoma and biologically indeterminate spitzoid tumors by RNA sequencing. *Mod Pathol*. 2016 Apr;29(4):359-69. **PMCID: PMC4811687**

Lee S, Opresko P, **Pappo A**, Kirkwood JM, Bahrami A. Association of TERT promoter mutations with telomerase expression in melanoma. *Pigment Cell Melanoma Res*. 2016 May;29(3):391-3. **PMCID: PMC5248652**

von Mehren M, Randall RL, Benjamin RS, Boles S, Bui MM, Conrad EU 3rd, Ganjoo KN, George S, Gonzalez RJ, Heslin MJ, Kane JM 3rd, Koon H, Mayerson J, McCarter M, McGarry SV, Meyer C, O'Donnell RJ, **Pappo AS**, Paz IB, Petersen IA, Pfeifer JD, Riedel RF, Schuetze S, Schupak KD, Schwartz HS, Tap WD, Wayne JD, Bergman MA, Scavone J. Soft Tissue Sarcoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw*. 2016 Jun;14(6):758-86.

Boikos SA, **Pappo AS**, Killian K, LaQuaglia MP, Weldon C, George S, Trent JC, vonMeheren M, Wright JA, Schiffman JD, Raygada M, Pacak K, Meltzer PS, Miettinen MM, Stratakis C, Janeway KA, Helman LJ. Molecular subtypes of KIT/PDGFR wild-type gastrointestinal stromal tumors. A report from the National Institutes of Health Gastrointestinal Stroma Tumor Clinic. *JAMA Oncol*. 2016 Jul 1;2(7):922-8. **PMCID: PMC5472100**

Navid F, Herzog C, Sandoval J, Daryani V, Stewart C, Gattuso J, Mandrell B, Phipps S, Chemaitilly W, Davidoff A, Shulkin B, Jenkins J, Mao S, Wu J, Schiff D, Rao B, **Pappo A**. Feasibility of Pegylated Interferon in Children and Young Adults with Resected Stage III Melanoma. *Pediatr Blood Cancer*. 2016 Jul;63(7):1207-13. **PMCID: PMC4877209**

Hurley C, McCarville MB, Shulkin BL, Mao S, Wu J, Navid F, Daw NC, **Pappo AS**, Bishop MW. Comparison of 18 FFDG-PET-CT and bone scintigraphy for evaluation of osseous metastases in newly diagnosed and recurrent osteosarcoma *Pediatr Blood Cancer* 2016 Aug;63(8):1381-6. **PMCID: PMC5082741**

Nagasubramanian R, Wei J, Gordon P, Rastatter JC, Cox MC, **Pappo A**. Infantile Fibrosarcoma With NTRK3-ETV6 Fusion Successfully Treated With the Tropomyosin-Related Kinase Inhibitor LOXO-101. *Pediatr Blood Cancer*. 2016 Aug;63(8):1468-70. **PMCID: PMC5074243**

Pinto E, Rodriguez-Galindo C, Choi J, Pounds S, Liu Z, Neale G, Finkelstein D, Hicks J, **Pappo A**, Figueiredo B, Ribeiro R, Zambetti G. Prognostic Significance of Major Histocompatibility Complex Class II Expression in Pediatric Adrenocortical Tumors: A St. Jude and Children's Oncology Group Study. *Clin Cancer Res*. 2016 Dec 15;22(24):6247-6255. **PMCID: PMC5159323**

Weldon CB, Madenci AL, Boikos SA, Janeway KA, George S, von Mehren M, **Pappo AS**, Schiffman JD, Wright J, Trent JC, Pacak K, Stratakis CA, Helman LJ, La Quaglia MP. Surgical Management of Wild-Type Gastrointestinal Stromal Tumors: A Report From the National Institutes of Health Pediatric and Wildtype GIST Clinic. *J Clin Oncol*. 2017 Feb 10;35(5):523-528. **PMCID: PMC5455315**

Corr AM, Liu W, Bishop M, **Pappo A**, Srivastava DK, Neel M, Rao B, Wilson T, Ness KK. Feasibility and functional outcomes of children and adolescents undergoing preoperative chemotherapy prior to a limb-sparing procedure or amputation. *Rehabil Oncol*. 2017 Jan;35(1):38-45. **PMCID: PMC5609724**

Fernandez-Pineda I, Hudson MM, **Pappo AS**, Bishop MW, Klosky JL, Brinkman TM, Srivastava DK, Neel MD, Rao BN, Davidoff AM, Krull KR, Mulrooney DA, Robison LL, Ness KK. Long-term functional outcomes and quality of life in adult survivors of childhood extremity sarcomas: a report from the St. Jude Lifetime Cohort Study. *J Cancer Surviv*. 2017 Feb;11(1):1-12. **PMCID: PMC5136514**

Grabski DF, **Pappo AS**, Krasin MJ, Davidoff AM, Rao BN, Fernandez-Pineda I. Long-term outcomes of pediatric and adolescent mediastinal germ cell tumors: a single pediatric oncology institutional experience. *Pediatr Surg Int*. 2017 Feb;33(2):235-244.

Agarwala SS, Lee SJ, Yip W, Rao UN, Tarhini AA, Cohen GI, Reintgen DS, Evans TL, Brell JM, Albertini MR, Atkins MB, Dakhil SR, Conry RM, Sosman JA, Flaherty LE, Sondak VK, Carson WE, Smylie MG, **Pappo AS**, Kefford RF, Kirkwood JM. Phase III Randomized Study of 4 Weeks of High-Dose Interferon- $\alpha$ -2b in Stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E1697). *J Clin Oncol*. 2017 Mar 10;35(8):885-892.

**PMCID: PMC5455684**

Seynnaeve B, Lee S, Borah S, Park Y, **Pappo A**, Kirkwood JM, Bahrami A. Genetic and Epigenetic Alterations of TERT Are Associated with Inferior Outcome in Adolescent and Young Adult Patients with Melanoma. *Sci Rep*. 2017 Apr 5;7:45704. **PMCID: PMC5381111**

Walterhouse DO, **Pappo AS**, Meza JL, Breneman JC, Hayes-Jordan A, Parham DM, Cripe TP, Anderson JR, Meyer WH, Hawkins DS. Reduction of cyclophosphamide dose for patients with subset 2 low-risk rhabdomyosarcoma is associated with an increased risk of recurrence: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. *Cancer*. 2017 Jun 15;123(12):2368-2375. **PMCID: PMC5662934**

Stewart E, Federico SM, Chen X, Shelat AA, Bradley C, Gordon B, Karlstrom A, Twarog NR, Clay MR, Bahrami A, Freeman BB 3rd, Xu B, Zhou X, Wu J, Honnell V, Ocarz M, Blankenship K, Dapper J, Mardis ER, Wilson RK, Downing J, Zhang J, Easton J, **Pappo A**, Dyer MA. Orthotopic patient-derived xenografts of paediatric solid tumours. *Nature*. 2017 Sep 7;549(7670):96-100. **PMCID: PMC5659286**

Karol SE, Yang W, Smith C, Cheng C, Stewart CF, Baker SD, Sandlund JT, Rubnitz JE, Bishop MW, **Pappo AS**, Jeha S, Pui CH, Relling MV. Palmar-plantar erythrodysesthesia syndrome following treatment with high-dose methotrexate or high-dose cytarabine. *Cancer*. 2017 Sep 15;123(18):3602-3608. **PMCID: PMC5589497**

Navid F, Santana VM, Neel M, McCarville MB, Shulkin BL, Wu J, Billups CA, Mao S, Daryani VM, Stewart CF, Kunkel M, Smith W, Ward D, **Pappo AS**, Bahrami A, Loeb DM, Willert JR, Rao BN, Daw NC. Phase II Trial Evaluating the Feasibility of Adding Bevacizumab to Standard Osteosarcoma Therapy. *Int J Cancer*. 2017 Oct 1;141(7):1469-1477.

Geoerger B, Bergeron C, Gore L, Sender L, Dunkel IJ, Herzog C, Brochez L, Cruz O, Nysom K, Berghorn E, Simsek B, Shen J, **Pappo A**. Phase II study of ipilimumab in adolescents with unresectable stage III or IV malignant melanoma. *Eur J Cancer*. 2017 Nov;86:358-363.

Federico SM, McCarville MB, Shulkin BL, Sondel PM, Hank JA, Hutson P, Meagher M, Shafer A, Ng CY, Leung W, Janssen WE, Wu J, Mao S, Brennan RC, Santana VM, **Pappo A**, Furman WL. A pilot trial of humanized anti-GD2 monoclonal antibody (hu14.18K322A) with chemotherapy and natural killer cells in children with recurrent/refractory neuroblastoma. *Clin Cancer Res*. 2017 Nov 1;23(21):6441-6449.

Tinkle CL, Fernandez-Pineda I, Sykes A, Lu Z, Hua CH, Neel MD, Bahrami A, Shulkin BL, Kaste SC, **Pappo A**, Spunt SL, Krasin MJ. Nonrhabdomyosarcoma soft tissue sarcoma (NRSTS) in pediatric and young adult patients: Results from a prospective study using limited-margin radiotherapy. *Cancer*. 2017 Nov 15;123(22):4419-4429.

**PMCID: PMC5673566**

Pinto EM, Rodriguez-Galindo C, Pounds SB, Wang L, Clay MR, Neale G, Garfinkle EAR, Lam CG, Levy CF, **Pappo AS**, Zambetti GP, Ribeiro RC. Identification of Clinical and Biologic Correlates Associated With Outcome in Children With Adrenocortical Tumors Without Germline TP53 Mutations: A St Jude Adrenocortical Tumor Registry and Children's Oncology Group Study. *J Clin Oncol*. 2017 Dec 10;35(35):3956-3963. **PMCID: PMC5721229**

Rudzinski ER, Anderson JR, Chi YY, Gastier-Foster JM, Astbury C, Barr FG, Skapek SX, Hawkins DS, Weigel BJ, **Pappo A**, Meyer WH, Arnold MA, Teot LA, Parham DM. Histology, fusion status, and outcome in metastatic rhabdomyosarcoma: A report from the Children's Oncology Group. *Pediatr Blood Cancer*. 2017 Dec 64(12). **PMCID: PMC5647228**

**Pappo AS**, Dirksen U. Rhabdomyosarcoma, Ewing Sarcoma, and Other Round Cell Sarcomas. *J Clin Oncol*. 2018 Jan 10;36(2):168-179.

Coccia PF, **Pappo AS**, Beaupin L, Borges VF, Borinstein SC, Chugh R, Dinner S, Folbrecht J, Frazier AL, Goldsby R, Gubin A, Hayashi R, Huang MS, Link MP, Livingston JA, Matloub Y, Millard F, Oeffinger KC, Puccetti D, Reed D,

Robinson S, Rosenberg AR, Sanft T, Spraker-Perlman HL, von Mehren M, Wechsler DS, Whelan KF, Yeager N, Gurski LA, Shead DA. Adolescent and Young Adult Oncology, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw*. 2018 Jan;16(1):66-97.

Pinto EM, Hamideh D, Bahrami A, Orr BA, Lin T, Pounds S, Zambetti GP, **Pappo AS**, Gajjar A, Agnihotri S, Broniscer A. Malignant rhabdoid tumors originating within and outside the central nervous system are clinically and molecularly heterogeneous. *Acta Neuropathol*. 2018 Feb 22;378(8):731-739.

Drilon A, Laetsch TW, Kummar S, Dubois SG, Lassen UN, Demetri GD, Nathenson M, Doebele RC, Farago AF, **Pappo AS**, Turpin B, Dowlati A, Brose MS, Mascarenhas L, Federman N, Berlin J, El-Deiry WS, Baik C, Deeken J, Boni V, Nagasubramanian R, Taylor M, Rudzinski E, Meric-Bernstam M, Sohal DPS, Ma PC, Raez LE, Hechtman JF, Benayed R, Ladanyi M, Tuch BB, Ebata K, Cruickshank S, Ku NC, Cox MC, Hawkins DS, Hong DS, Hyman DM. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. *N Engl J Med*. 2018 Feb;378:731-739. **PMCID: PMC5857389**

Laetsch TW, DuBois SG, Mascarenhas L, Turpin B, Federman N, Albert CM, Nagasubramanian R, Davis JL, Rudzinski E, Feraco AM, Tuch BB, Ebata KT, Reynolds M, Smith S, Cruickshank S, Cox MC, **Pappo AS**, Hawkins DS. Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study. *Lancet Oncol*. 2018 May;19(5):705-714. **PMCID: PMC5949072**

Wakefield DV, Eaton BR, Dove APH, Hsu CY, Merchant TE, **Pappo A**, Davidoff AM, Esiashvili N, Krasin MJ, Lucas JT Jr. Is there a role for salvage re-irradiation in pediatric patients with locoregional recurrent rhabdomyosarcoma? Clinical outcomes from a multi-institutional cohort. *Radiother Oncol*. 2018 Dec; 129(3):513-519.

Detti L, Fletcher NM, Saed GM, Sweatman TW, Uhlmann RA, **Pappo A**, Peregrin-Alvarez I. Xenotransplantation of pre-pubertal ovarian cortex and prevention of follicle depletion with anti-Müllerian hormone (AMH). *J Assist Reprod Genet*. 2018 Oct;35(10):1831-1841. **PMCID: PMC6150887**

Stewart E, McEvoy J, Wang H, Chen X, Honnell V, Ocarz M, Gordon B, Dapper J, Blankenship K, Yang Y, Li Y, Shaw TI, Cho JH, Wang X, Xu B, Gupta P, Fan Y, Liu Y, Rusch M, Griffiths L, Jeon J, Freeman BB 3rd, Clay MR, **Pappo A**, Easton J, Shurtleff S, Shelat A, Zhou X, Boggs K, Mulder H, Yergeau D, Bahrami A, Mardis ER, Wilson RK, Zhang J, Peng J, Downing JR, Dyer MA. Identification of Therapeutic Targets in Rhabdomyosarcoma through Integrated Genomic, Epigenomic, and Proteomic Analyses. *Cancer Cell*. 2018 Sep 10;34(3):411-426.e19. **PMCID: PMC6158019**

Halalshah H, Kaste SC, Navid F, Bahrami A, Shulkin BL, Rao B, Kunkel M, Artz N, **Pappo A**. The role of routine imaging in pediatric cutaneous melanoma. *Pediatr Blood Cancer*. 2018 Dec;65(12):e27412. **PMCID: PMC6193828**

DuBois SG, Laetsch TW, Federman N, Turpin BK, Albert CM, Nagasubramanian R, Anderson ME, Davis JL, Qamoos HE, Reynolds ME, Cruickshank S, Cox MC, Hawkins DS, Mascarenhas L, **Pappo AS**. The use of neoadjuvant larotrectinib in the management of children with locally advanced TRK fusion sarcomas. *Cancer*. 2018 Nov 1;124(21):4241-4247. **PMCID: PMC6263791**

Brady SW, Ma X, Bahrami A, Satas G, Wu G, Newman S, Rusch M, Putnam DK, Mulder HL, Yergeau D, Edmonson MN, Easton J, Alexandrov LB, Chen X, Mardis ER, Wilson RK, Downing JR, **Pappo AS**, Raphael BJ, Dyer MA, Zhang J. The Clonal Evolution of Metastatic Osteosarcoma as Shaped by Cisplatin Treatment. *Molecular Cancer Research*. 2019 Apr;17(4):895-906.

#### **Books:**

Pediatric Bone and Soft Tissue Sarcomas. **Alberto Pappo**. Editor. Springer Berlin, 2005 pp1-240.

#### **Book Chapters and Monographs:**

**Pappo AS**, Kuttesch JF, Santana VM, Shapiro DN. Pediatric Tumors. In: Abeloff MD, Armitage JO, Lichter AS, Niederhuber JE, eds. *Clinical Oncology*. Churchill Livingstone 1847-1887, 1995.

- Pappo AS**, Pratt CB. Soft tissue sarcomas in children. Verweij J, Pinedo HM, Suit HD. *Soft Tissue Sarcomas: Present achievements and future prospects*. Kluwer Academic Publishers, 1997 Boston. pp 205-222.
- Pappo AS**. Other soft tissue sarcomas and benign tumors. In: Behrman RE, Kliegman RM, Arvin AM, eds. *Nelson Textbook of Pediatrics*. WB Saunders 1466-1467, 1475-1477, 1996.
- Pappo AS**, Kaste SC, Rao BN, Pratt CB. Childhood melanoma. In: Balch CM, Houghton AN, Sober AJ, Soong SJ, eds. *Cutaneous melanoma*. Quality Medical Publishing, 1997, St. Louis Missouri. pp 175-186.
- Pappo AS**, Shapiro DN. Rhabdomyosarcoma: Biology and Therapy. In: Walterhouse DO and Cohn SL. *Diagnostic and Therapeutic Advances in Pediatric Oncology*. Kluwer Academic Publishers, pp 309-339, 1997.
- Pappo AS**, Crist WM. Rhabdomyosarcoma of the head and neck in children. In Robbins KT, ed. *Advances in Head and Neck Oncology*. Singular publishing, 1998, San Diego, Ca. pp 119-132.
- Pappo AS**, Rodriguez-Galindo C, Dome JS, Santana VM. Pediatric Tumors. In Abeloff MD, Armitage JO, Lichter AS, Niederhuber JE, ed. *Clinical Oncology*. Churchill Livingstone. 2000, Philadelphia Pennsylvania. pp. 2346-2401.
- Pappo A**, Pring K. The Ewing's sarcoma family of tumors. In Steen G PhD and Mirro J, M.D. eds. *Childhood Cancer. A handbook from St. Jude Children's Research Hospital*. Perseus Publishing, 2000, Cambridge, MA. pp 383-389.
- Pappo A**, Pring K. Rhabdomyosarcoma. In Steen G PhD and Mirro J, M.D. eds. *Childhood Cancer. A handbook from St. Jude Children's Research Hospital*. Perseus Publishing, 2000, Cambridge, MA.. pp 425-431.
- Pratt CB, **Pappo AS**. Management of infrequent cancers of childhood. In Pizzo PA and Poplack DG. *Principles and practice of pediatric oncology*. Lippincott Williams and Wilkins 2002 Philadelphia PA pp 1149-1175.
- Miser JS, **Pappo AS**, Triche TJ, Merchant TE, Rao BN. Other soft tissue sarcomas of childhood. In Pizzo PA and Poplack DG. *Principles and practice of pediatric oncology*. Lippincott Williams and Wilkins 2002 Philadelphia PA pp 1017-1050.
- Rodriguez-Galindo C, **Pappo AS**. Less frequently encountered tumors of childhood. In Kufe DW, Pollock RE, Weichselbaum RR, Bast RC, Gansler TS, Holland JF, Frei W. *Cancer Medicine*. BC Decker Inc 2003 Hamilton, ON pp 2349-2356.
- Pappo AS**, Furman WL. Management of infrequent cancers of childhood. In Pizzo PA and Poplack DG. *Principles and practice of pediatric oncology*. Lippincott Williams and Wilkins, Philadelphia, PA 2006 Fifth Edition pp 1172-1201.
- Ocku MF, Merchant TE, **Pappo AS**, Hicks J, Andrassy RJ, Horowitz ME. Nonrhabdomyosarcomatous soft tissue sarcomas. In Pizzo PA, Poplack DG *Principles and practice of pediatric oncology*. Lippincott Williams and Wilkins. Philadelphia, PA 2006, Fifth Edition, pp1031-1073.
- Pappo AS**, Barr F, Wolden S. Pediatric Rhabdomyosarcoma: Biology and Results of the North American Intergroup Rhabdomyosarcoma Trials. In Pappo AS *Pediatric bone and soft Tissue sarcomas*. Springer, Berlin 2005 pp103-132.
- Rodriguez-Galindo C, **Pappo AS**. Less frequently encountered tumors of childhood. In Kufe DW, Bast RC, Hait WN, Hong WK, Pollock RE, Weichselbaum RR, Holland JF, Frei W. *Cancer Medicine*. BC Decker Inc 2006 Hamilton, ON. pp 1976-1982.
- Herzog C, **Pappo A**, Bondy M, Bleyer A, Kirkwood JM. Malignant Melanoma. In Bleyer WA, O'Leary M, Barr F, Ries LAG, Andreson B, Valle CG. *Cancer epidemiology in older adolescents and young adults 15 to 29 years of age, including SEER incidence and survival: 1975:2000*. Bethesda, MD, 2006.
- Herzog CE, Bleyer WA, **Pappo AS**. Malignant melanoma. In Bleyer W, Barr RD *Cancer in adolescents and young adults*. Springer-Verlag Berlin Heidelberg 2007. pp 271-291.
- Russell HV, **Pappo AS**, Nuchtern JG, Kornguth DG, Wang LL. Solid tumors of childhood. In DeVita VT Jr, Lawrence

TS, Rosenberg SA. Cancer principles and practice of oncology. Lippincott Williams and Wilkins .Philadelphia, PA 2008, Eighth edition, pp 2043-2083.

Albritton K, Goldberg JM, **Pappo A**. Rare tumors of childhood. In Orkin SH, Fisher DE, Look AT, Lux SE, Ginsburg D, Nathan DG. Oncology of infancy and childhood. Saunders Elsevier. Philadelphia PA 2009. pp 989-1013.

Ocku MF, **Pappo AS**, Hicks J, Million L, Andrassy RJ, Spunt SL. The nonrhabdomyosarcoma soft tissue sarcomas. In Pizzo PA, Poplack DG. Principles and practice of pediatric oncology. 6th edition. Lippincott Williams and Wilkins. Philadelphia, PA 2011. pp 954-986.

**Pappo AS**, Rodriguez-Galindo C, Furman WL. Management of infrequent cancers of childhood. In Pizzo PA, Poplack DG. Principles and practice of pediatric oncology. 6th edition. Lippincott Williams and Wilkins. Philadelphia, PA 2011. pp 1098-1123.

Wang LL, Yustein J, Louis C, Russell H, **Pappo AS**, Paulino A, Nuchtern J, Chintagumpala M. In De Vitta V, Lawrence T, Rosenberg S: Cancer principles and practice of oncology. 9th edition. Lippincott Williams Wilkins Philadelphia, PA 2011. pp 1760-1792.

**Pappo AS**, Eigentler TK, Garbe C, Collini P, Ferrari A, Rossler J. Rare Tumors of the skin and subcutaneous tissue. In Schneider DT, Brecht IB, Olson TA, Ferrari A. Rare tumors in children and adolescents. Springer Berlin 2012. pp 431-454.

**Pappo AS**, Reaman GH. Introduction to rare cancers in childhood. In Raghavan D, Blanke CD et al. Textbook of uncommon cancers. 4th edition. Wiley Blackwell NJ, 2012. pp 847-850.

**Pappo AS**, Furman WL. Uncommon tumors of the gastrointestinal tract. In Raghavan D, Blanke CD et al. Textbook of uncommon cancers. 4th edition. Wiley Blackwell NJ, 2012. pp 851-866.

**Pappo AS**, Rodriguez-Galindo C. In Raghavan D, Blanke CD et al. Textbook of uncommon cancers. 4th edition. Wiley Blackwell NJ, 2012. Malignant tumors of the skin and subcutaneous tissue in children. pp 943-957.

**Pappo AS**, Navid F, Brennan R, Krasin M, Davidoff A, Furman W. In De Vitta V, Lawrence T, Rosenberg S: Cancer: Principals and Practice of Oncology. 10th edition. Wolters Kluwer, PA. Solid Tumors of Childhood pp 1465-1499, 2015.

Goldberg JM, **Pappo AS**, Bishop M. Rare tumors of childhood. In Orkin SH, Fisher DE, Ginsburg D. Look AT, Lux SE, Nathan DG. Natanhan and Oski's Hematology and Oncology of Infancy and Childhood. 8th edition. Elsevier, Philadelphia, PA, pp 2123-2145. 2015.

**Pappo AS** and Reaman GH. Introduction to rare pediatric malignancies. In Raghavan D, Ahluwalia MS, Blanke CD, Brown J, Kim ES, Reaman GH, Sekeres MA. Textbook of uncommon cancer Wiley Blackwell pp 1069-1071, Hoboken, NJ, 2017.

**Pappo AS**, Furman WL Uncommon tumors off the gastrointestinal tract. In Raghavan D, Ahluwalia MS, Blanke CD, Brown J, Kim ES, Reaman GH, Sekeres MA. Textbook of uncommon cancer Wiley Blackwell pp 1072-1087, Hoboken, NJ, 2017.

**Pappo AS** and Rodriguez-Galindo C. Malignant tumors of the skin and subcutaneous tissue in children In Raghavan D, Ahluwalia MS, Blanke CD, Brown J, Kim ES, Reaman GH, Sekeres MA. Textbook of uncommon cancer Wiley Blackwell pp 1172-1189, Hoboken, NJ, 2017.

### **Reviews and Conference Proceedings:**

**Pappo AS**. Rhabdomyosarcoma and other soft tissue sarcomas of childhood. Curr Opin Oncol 6:397-402, 1994.

**Pappo AS**, Shapiro DN, Crist WM, Maurer HM. Biology and therapy of pediatric rhabdomyosarcoma. J Clin Oncol 13:2123-2139, 1995.

**Pappo AS.** Rhabdomyosarcoma and other soft tissue sarcomas in children. *Curr Opin Oncol* 8:311-316, 1996.

**Pappo AS,** Shapiro DN, Crist WM. Rhabdomyosarcoma: Biology and treatment. *Pediatr Clin North Am* 44:953-972, 1997.

**Pappo AS,** Parham DM, Rao BN, Lobe TE. Soft tissue sarcomas in children. *Semin Surg Oncol* 16:121-143, 1999.

McCarville MB, Spunt SL, **Pappo AS.** Rhabdomyosarcoma in pediatric patients. The good, the bad and the unusual. *AJR* 176:1563-1569, 2001.

Spunt S, Thompson SJ, **Pappo AS.** Brain metastases in pediatric solid tumors. *Forum* 11: 75-83, 2001.

**Pappo AS.** Melanoma in children and adolescents. *Eur J Cancer* 39:2651-2661, 2003.

Rodriguez-Galindo C, Spunt SL, **Pappo AS.** Treatment of Ewing sarcoma family of tumors: Current status and outlook for the future. *Med Pediatr Oncol* 40:276-287, 2003.

Gupta AA, **Pappo AS.** New drugs for the treatment of metastatic or refractory soft tissue sarcomas in children. *Future Oncology* 2:675-685, 2006.

**Pappo AS,** Janeway K A Pediatric gastrointestinal stromal tumors. *Hematol Oncol Clin N Am* 23:15–34, 2009.

Kim SY, Janeway K, **Pappo A.** Pediatric and wild-type gastrointestinal stromal tumor: new therapeutic approaches. *Curr Opin Oncol* 22:347-350, 2010. **PMCID: PMC2949288**

**Pappo AS,** Janeway K, LaQuaglia M, Kim S. Special considerations in pediatric gastrointestinal stromal tumors. *J Surg Oncol* 2011 Dec;104(8):928-32.

Pui CH, Gajjar A, Kane JR, Qaddoumi IA, **Pappo AS.** Challenging issues in pediatric oncology. *Nat Rev Clin Oncol.* 2011 June 28;8:540-9. **PMCID: PMC3234106**

Jordan AH, **Pappo A.** Management of Desmoplastic Small Round-cell Tumors in Children and Young Adults. *J Pediatr Hematol Oncol.* 2012 May;34 Suppl 2:S73-5.

Janeway KA, **Pappo A.** Treatment guidelines for gastrointestinal stromal tumors in children and young adults. *J Pediatr Hematol Oncol.* 2012 May;34 Suppl 2:S69-72.

Neier M, **Pappo A,** Navid F. Management of melanomas in children and young adults. *J Pediatr Hematol Oncol.* 2012 May;34 Suppl 2:S51-4.

Glick RD, Pashankar FD, **Pappo A,** Laquaglia MP. Management of pancreatoblastoma in children and young adults. *J Pediatr Hematol Oncol.* 2012 May;34 Suppl 2:S47-50.

**Pappo AS.** Treating Rare Cancer in Children: The Importance of Evidence. *Am Soc Clin Oncol Educ Book.* 2012;32:586-88.

**Pappo AS.** Pediatric melanoma: the whole (genome) story. *Am Soc Clin Oncol Educ Book.* 2014:e432-5.

Chen X, **Pappo A,** Dyer MA. Pediatric solid tumor genomics and developmental pliancy *Oncogene.* 2015 Oct 8;34(41):5207-15. **PMCID: PMC4522402**

Quinn E, McGee R, Nuccio R, **Pappo AS,** Nichols KE. Genetic Predisposition to Neonatal Tumors. *Curr Pediatr Rev.* 2015;11(3):164-78.

#### **Editorials and Commentaries:**

**Pappo AS**, Pratt CB. Melanoma in children. [Letter]. N Engl J Med 333:256, 1995.

**Pappo AS**, Shapiro DN, Crist WM, Maurer HM. Biology and therapy of pediatric rhabdomyosarcoma. [Letter]. J Clin Oncol 14:323, 1996.

**Pappo AS**, Santana VM, Furman WL, Kun LE, Walter A, Jenkins JJ, Rao BN, Pratt CB. Post-irradiation mesothelioma. [Letter]. Cancer 79:192-193, 1997.

Rao BN, **Pappo AS**. Commentary on "Pediatric Soft Tissue Sarcoma: Multidisciplinary Management of Pediatric Soft-Tissue Sarcoma" by Holly Neville, R. Beverly Raney, and Richard Andrassy. Oncology 14:1482-1485, 2000.

Spunt SL, **Pappo AS**. Cyclophosphamide and etoposide for pediatric solid tumors. J Clin Oncol 18: 3741-3742, 2000 [letter].

**Pappo AS**, Grier HE. A tribute to Dr. Charles Pratt. J Pediatr Hematol Oncol 24:242-243, 2002.

Pui CH, **Pappo A**, Gajjar A, Downing JR. Redefining "rare" cancers. Lancet Oncology. 2016 Feb;17(2):138-9.

### **Case reports:**

**Pappo AS**, Cheah MSC, Saldivar VA, Britton HA, Parmley RT: Disseminated primitive neuroectodermal tumor: Diagnosis using immunocytochemistry, electron microscopy and molecular probes. Cancer 63:2515-2521, 1989.

**Pappo AS**, Buchanan GR: Acute splenic sequestration in a two month old infant with sickle cell anemia. Pediatrics 84:578-579, 1989.

**Pappo A**, Schneider N, Sanders J, Buchanan GR. Secondary myelodysplastic syndrome complicating therapy for osteogenic sarcoma. Cancer 68:1373-1375, 1991.

Fisher R, Kaste S, Parham DM, Shapiro DN, **Pappo AS**. Ewing's sarcoma as a second malignant neoplasm in a child previously treated for Wilms' tumor. Am J Pediatr Hematol Oncol 17:76-80, 1995.

Venkastewaran L, Jenkins JJ, Kaste SC, Shurtleff S, Downing J, **Pappo AS**. Disseminated intrathoracic desmoplastic small round cell tumor. J Pediatr Hematol Oncol 19:172-175, 1997.

Antillon F, Kaste SC, Jenkins JJ, Shurtleff SA, Merchant T, Downing JR, **Pappo AS**. Peripheral neuroepithelioma (Ewing sarcoma) of bone as a second malignant neoplasm in a child previously treated for acute lymphoblastic leukemia. J Pediatr Hematol Oncol 19:473-476, 1997.

Antillon F, Raimondi S, Sandlund JT, Behm F, **Pappo A**. Diffuse primary lymphoma of bone with t(3;22). J Pediatr Hematol/Oncol 20:552-555, 1998.

Arnaout MK, **Pappo AS**. Kaposiform hemangioendothelioma with associated Kasabach- Merritt phenomenon. J Pediatr 133:788, 1998.

Wodowski K, Hill DA, **Pappo AS**, Shochat SJ, Kun LE, Spunt SL. A chemosensitive pediatric extraosseous osteosarcoma: Case report and review of the literature. J Pediatr Hematol/Oncol 25:73-77, 2003.

Ramphal R, Manson D, Viero S, Zielenska M, Gerstle T, **Pappo A**. Retroperitoneal infantile fibrosarcoma: clinical, molecular, and therapeutic aspects of an unusual tumor. Pediatr Hematol Oncol 20:635-642, 2003.

Al-Saad K, Khanani MF, Naqvi A, Krafchik B, Grant R, **Pappo A**. Sweet syndrome developing during treatment with all-trans retinoic acid in a child with acute myelogenous leukemia. J Pediatr Hematol Oncol 26:197-199, 2004.

Price VE, Fletcher JA, Zielenska, M, Cole W, Viero S, Manson DE, Stuart M, **Pappo AS**. Imatinib mesylate: An attractive alternative in young children with large, surgically challenging dermatofibrosarcoma protuberans. *Pediatr Blood cancer* 44:511-515, 2005.

Katz SL, Das P, Ngan B, Manson D, **Pappo AS**, Sweezey NB, Solomon MP. Remote intrapulmonary spread of recurrent respiratory papillomatosis with malignant transformation. *Pediatr Pulmonol* 39:185-188, 2005.

Bernhardt BM, Hicks JM. **Pappo AS**. Administration of high-dose Interleukin-2 in a 2 year old with metastatic melanoma. *Pediatr Blood Cancer* 53:1346-8, 2009.

Wahid FN, Malkan AD, **Pappo A**, Wright BB, Adefeyisan S, Sandoval JA, Severe anaphylactic shock due to methylene blue. *J Ped Surg. Case Reports* 2:117-118, 2014.

Fernandez-Pineda I, Jenkins JJ, Santiago TC, Prajapati HJ, **Pappo AS**. Awareness of intramuscular capillary type hemangioma in the differential diagnosis of soft-tissue tumors in children. *Pediatr Blood Cancer*. 2016 Dec;63(12):2252-2253.

Halalsheh H, McCarville MB, Neel M, Reynolds M, Cox MC, Pappo AS. Dramatic bone remodeling following larotrectinib administration for bone metastasis in a patient with TRK fusion congenital mesoblastic nephroma. *Pediatr Blood Cancer*. 2018 Oct;65(10):e27271. Epub 2018 Jun 12.

## Abstracts

**Pappo A**, Vietti T, Whitehead V, Ragab A, Kamen B: A phase II trial of trimetrexate in the treatment of childhood acute leukemia. *Proc Am Soc Clin Oncol* 9:221, 1990.

**Pappo A**, Buchanan GR: Secondary myelodysplastic syndrome complicating therapy for osteosarcoma. *Clin Res* 38:998A, 1990.

**Pappo A**, Buchanan GR: Predictors of bacteremia in febrile neutropenic children with cancer. *Proc Am Soc Clin Oncol* 10:331, 1991.

**Pappo AS**, Vats T, Williams TE, Bernstein M, Kamen BA: Phase I trial of trimetrexate in pediatric solid tumors: A Pediatric Oncology Group study. *Proc Am Soc Clin Oncol* 10:314, 1991.

Mustafa M, **Pappo A**, Cash J, Winick N, Buchanan GR: Aerosolized pentamidine prophylaxis against *Pneumocystis carinii* pneumonia in cancer patients intolerant or allergic to trimethoprim/sulfamethoxazole. *Pediatr Res* 29:146A, 1991.

**Pappo AS**, Fields B, Buchanan GR: Impact of new diseases and therapies on the etiology of childhood macrocytosis. *Pediatr Res* 29:147A, 1991. Presented at The Society of Pediatric Research (SPR), New Orleans, Louisiana, May 2, 1991.

**Pappo A**, Meyer WH, Marina N, Mahmoud H, Pratt CB. Chemotherapy for recurrent osteosarcoma: Is it worth it? *Proc Am Soc Clin Oncol* 111:368, 1992.

Chan WC, Carrol A, Alvarado CS, Phillips S, Gonzalez-Crussi F, Kurczynski E, **Pappo A**, Emani A, Boman P, Head DR. Acute megakaryoblastic leukemia in infancy with t(1;22) (p13;q13) abnormality. *Lab Invest* 66:76A, 1992.

Mustafa MM, **Pappo A**, Winick N, Buchanan GR. Aerosolized pentamidine (AP) for the prevention of *Pneumocystis carinii* pneumonia (PCP) in children with Cancer (Ca) intolerant or allergic to trimethoprim/sulfamethoxazole (TMP/SMX). Presented at the 32nd ICAAC Meeting, Anaheim, California, 1992.

**Pappo A**, Crist WM, Rowe S, Ashmun RA, Maurer HM, Asmar L, Shapiro DN. Tumor cell DNA content predicts outcome in children and adolescents with clinical group III embryonal rhabdomyosarcoma. *Proc Am Soc Clin Oncol* 12:411, 1993. Presented at the ASCO Meeting, Orlando, Florida, June 17, 1993.



Marina N, Shema S, Rodman J, Bowman L, Furman W, **Pappo A**, Meyer W, Pratt C. Ifosfamide, carboplatin and etoposide (ICE) combined with human granulocyte-macrophage colony-stimulating factor (GM-CSF) in children with recurrent solid tumors. *Proc Am Soc Clin Oncol* 12:422, 1993.

Mahmoud H, Foreman N, Pui C-H, Hancock M, **Pappo A**, Rivera G, Crist W. Increased risk of cerebrovascular complications in adolescent girls during induction therapy for acute lymphoblastic leukemia. *Soc Int Oncol Pediatr (SIOP)*, 1993.

**Pappo A**, Crist WM, Rowe S, Ashmun RA, Maurer HM, Asmar L, Shapiro DN. Tumor cell DNA content predicts outcome in children and adolescents with clinical group III embryonal rhabdomyosarcoma. *Med Pediatr Oncol* 21:549, 1993. Presented at the XXV International Society of Pediatric Oncology, San Francisco, California, October 1993.

Regine WF, Fontanesi J, Bowman L, **Pappo A**, Coffey D, Kun LE. Evaluation of local control with selective use of low-dose irradiation following induction/preoperative chemotherapy for locally advanced rhabdomyosarcoma. *ASTRO*, 1993.

Fontanesi J, **Pappo A**, Taylor M, Rao B, Hurwitz C, Parham D, Kun LE. The role of irradiation in the management of newly diagnosed synovial sarcoma (SS). *ASTRO*, 1993.

Kaste SC, **Pappo AS**, Pratt CB. Malignant melanoma in children: imaging spectrum. *Soc Ped Radiology*, (Abstract 54) 1994. Presented at the 37th Annual Meeting of the Society of Pediatric Oncology. Colorado, Springs, CO, May, 1994.

**Pappo A**, Fontanesi J, Hurwitz C, Rao R, Luo X, Parham D, Pratt C. Synovial sarcoma (SS) in children and adolescents. The St. Jude experience. *Proc Am Soc Clin Oncol* 13:413, 1994. Presented at the 30th Annual Meeting of the American Society of Clinical Oncology, Dallas, Texas, May, 1994.

Kuttesch J, Parham D, Luo X, Meyer W, Bowman L, Shaprio D, **Pappo A**, Crist W, Beck W, Houghton P. Pglycoprotein expression at diagnosis does not predict worse outcome in pediatric rhabdomyosarcoma (RMS). *Proc Am Soc Clin Oncol* 13:413, 1994.

Regine W, Greenwald C, Kumar P, Ballas D, **Pappo A**, Shaprio D, Bowman L, Rao B, Kun L. Use of altered radiation (RT) dose and fractionation in patients with unresectable rhabdomyosarcoma (RMS) based upon disease status following induction therapy: The St. Jude experience. *Proc Am Soc Clin Oncol* 13:419, 1994.

Marina N, **Pappo A**, Parham D, Fletcher B, Greenwald C, Rao B, Pratt C, Meyer W. Intensified induction treatment for newly diagnosed childhood Ewing's sarcoma (ES) and peripheral neuroepithelioma (PN). *Proc Am Soc Clin Oncol* 13:419, 1994.

Pratt CB, Meyer WH, Marina N, **Pappo A**, Luo X, Kun L. Ewing sarcoma under the age of 12 years. *Proc Am Soc Clin Oncol* 13:418, 1994.

Priest J, Watterson L, Dehner L, Friend S, McIntyre J, Strong L, Hansen M, Byrd B, Feusner J, Amylon M, Bostrom B, Langston C, **Pappo A**. Childhood pleuropulmonary blastoma (PPB) as a unique marker for familial childhood neoplasms. *Proc Am Soc Clin Oncol* 13:186, 1994.

Greenwald CA, Marina N, Pappo A, Meyer WH, Kauffman WM, Parham DM, Rao BN, Fang L, Kun LE. Control of localized Ewing's sarcoma <8 cm in size with therapy including 36 Gy local field irradiation. Evolving role of radiation in pediatric oncology meeting. Philadelphia, Pennsylvania, 1995.

Sonnichsen D, Schuetz E, Schuetz J, **Pappo A**, Relling M. Variability in human in vitro metabolism of paclitaxel. *Am Soc Clin Pharm Therap*, 1995.

**Pappo A**, Kaste S, Rao B, Cain A, Jenkins J, Hazard M, Shearer P, Pratt C. Therapy for advanced stage pediatric malignant melanoma with interferon (IFN), vincristine (V), dactinomycin (A), cyclophosphamide (C), cisplatin (CDDP), and etoposide (VP-16) meeting, Houston, Texas, February 1995.

**Pappo A**, Bowman L, Parham D, Luo X, Rao B, Crist W, Meyer W. Window therapy with high-dose methotrexate (HDMTX) in newly diagnosed advanced stage rhabdomyosarcoma (RMS). *Proc Am Soc Clin Oncol* 14:452 (abstr 1452), 1995.

Ortega JA, Donaldson S, Ivy P, **Pappo A**, Maurer H. Venous-occlusive disease (VOD) of the liver: A complication of vincristine-actinomycin D-cyclophosphamide (VAC) therapy for rhabdomyosarcoma (RMS). A report for the Intergroup Rhabdomyosarcoma Study (IRS) Group. *Proc Am Soc Clin Oncol* 14:440 (abstr 1401), 1995.

Aquino V, **Pappo A**, Mustafa M, Tkaczewski I, Buchanan G. Predictors of bacteremia in febrile neutropenic children with cancer: an analysis of risk factors. *Proc Am Soc Clin Oncol* 14:536 (abstr 1773), 1995.

Mustafa M, Aquino V, **Pappo A**, Tkaczewski I, Buchanan G. A pilot study of outpatient management of febrile neutropenic children with cancer who are at low risk for bacteremia. *Proc Am Soc Clin Oncol* 14:527 (abstr 1734), 1995.

Rao BN, Lynch M, Meyer W, **Pappo A**, Pratt C, Marina N. Limb salvage for skeletal sarcomas in children and adolescents. Submitted to the European Musculo-Skeletal Oncology Society and American Musculo-Skeletal Tumour Society Meeting, 1995.

Rao BN, **Pappo A**, Bowman L, Pratt C, Greenwald C, Meyer W. Non-rhabdomyosarcoma soft tissue sarcoma (NRSTS) of the extremity: Prognostic factors influencing survival in children. Submitted to the European Musculo-Skeletal Oncology Society and American Musculo-Skeletal Tumour Society Meeting, 1995.

**Pappo A**, Hazard M, Cain A, Rao B, Meyer W, Pratt C. Brain metastases from Ewing's sarcoma (ES) and rhabdomyosarcoma (RMS) in pediatric patients. *Proc Clin Oncol*, 1996.

Rodriguez-Galindo C, **Pappo A**, Cain A, Rao B, Kaste S, Pratt C. Brain metastases in pediatric patients with malignant melanoma. *Proc Am Soc Clin Oncol* 15:439 (abstr 1365), 1996.

Pratt CB, Meyer WH, Rao B, **Pappo A**, Fleming ID, Luo X, Cain A, Kaste SC. Comparison of primary osteosarcoma (OS) and secondary OS of flat bones. *Proc Am Soc Clin Oncol* 15:523 (1687), 1996.

Hongeng S, Kaste S, **Pappo A**, Aggarwal R, Meyer W, Pratt C. Nasopharyngeal rhabdomyosarcoma (NPRMS): Clinical features, outcome, and significance of persistent radiographic findings. *Proc Am Soc Clin Oncol* 15:462 (abstr 1455), 1996.

Rao BN, Lynch M, Meyer W, **Pappo A**, Bowman L, Kaste SC, Pratt CB, Cremer L, Neel M. Limb salvage for skeletal sarcoma in children and adolescents. *Med Pediatr Oncol* 27:254 (abstr 171), 1996.

Neel M, Rao BN, Meyer W, **Pappo A**, Kaste SC, Pratt CB, Cremer L, Lynch M. Functional outcome following limb salvage surgery about the knee. *Med Pediatr Oncol* 27:247 (abstr 146), 1996.

Gross E, Rao BN, **Pappo A**, Bowman LC, Shearer P, Greenwald C, Kaste SC, Pratt CB. Soft tissue sarcomas (STS) of the hand and foot. *Med Pediatr Oncol* 27:338 (abstr P-206), 1996.

Michalkiewicz E, Rao BN, Bowman LC, **Pappo A**, Kaste SC, Hudson MM, Greenwald C, Walter A, Pratt CB. Complications of pelvic exenteration for GU RMS. Submitted IPSO 1996.

Gross E, Rao BN, **Pappo AS**, Bowman LC, Shearer P, Kaste SC, Walter A, Pratt CB. Epithelioid sarcoma in children. Submitted to IPSO 1996.

Meyer WH, Pratt CB, Rao BN, Luo X, Jenkins JJ, Shearer P, **Pappo A**, Neff J, Harper J. Curative therapy for osteosarcoma without cisplatin-Preliminary experience with SJCRH OS-91. *Med Pediatr Oncol* 27:226 (abstr 0-62), 1996.

Zamboni WC, Santana V, Gajjar A, Meyer WH, **Pappo A**, Houghton PJ, Stewart CF. Pharmacokinetically guided dose adjustment reduces variability in topotecan (TPT) systemic exposure in children with solid tumors. *Proc Am Soc Clin Oncol* 16:205a, (abstr 717), 1997.

Santana V, Zamboni W, Gajjar A, **Pappo A**, Houghton P, Meyer W, Stewart C. Pharmacokinetically guided use of topotecan (TPT), given (daily x5) x2 in children with relapsed solid tumors. Proc Am Soc Clin Oncol 16:51a, (abstr 1839), 1997.

Meyer WH, Pratt CB, Rao BN, Luo X, Jenkins JJ, Shearer P, **Pappo A**, Mahmoud H, Neff J, Harper J. Curative therapy for osteosarcoma without cisplatin-preliminary results of SJCRH OS-91. Proc Am Soc Clin Oncol 16:512a (abstr 1842), 1997.

Rodriguez-Galindo C, **Pappo A**, Marina N, Cain A, Meyer W, Scurto P, Wilimas J. Hematologic abnormalities after intensive treatment of pediatric Ewing's sarcoma family of tumors (ESFT's). Proc Am Soc Clin Oncol 16:524a (abstr 1886), 1997.

Marina N, **Pappo A**, Parham D, Fletcher B, Kun L, Pratt C, Meyer W. Intensified chemotherapy for pediatric Ewing sarcoma (ES) or peripheral neuroepithelioma (PN). Proc Amer Soc Clin Oncol 16:526a (abstr 1896), 1997.

**Pappo AS**, Rao BN, Jenkins JJ, Merchant T, Poquette CA, Cain A, Pratt CB. Metastatic nonrhabdomyosarcomatous soft-tissue sarcomas in children and adolescents: the St. Jude Children's Research Hospital experience. Med Pediatr Oncol. 1999 Aug;33(2):76-82. (Poster presentation)

Furman WL, Stewart CF, Pratt CB, Santana VM, Bowman LB, Ma MK, Hoffer F, Meyer WH, Pappo A, Walter A, Houghton PJ. A phase I trial of irinotecan (CPT-11) in children with relapsed solid tumors. Proc Amer Soc Clin Oncol 17: 187a, 1998.

Rodriguez-Galindo C, **Pappo A**, Marina N, Poquette C, Santana VM, Cain A, Raimondi S, Behm F, Meyer W. Myelodysplasia (MDS) following intensive therapy for Ewing's sarcoma family of tumors (ESFT). Proc Amer Soc Clin Oncol 17: 540a, 1998.

**Pappo A**, Anderson J, Grier H, Wharam M, Breitfeld P, Hawkins D, Raney B, Womer R, Parham D, Qualman S, Crist W. Survival after relapse in children with rhabdomyosarcoma (RMS): An analysis of 609 patients (pts) enrolled on IRS-III, IRS-IVpilot (IVp) or IRS-IV. A report from the Intergroup Rhabdomyosarcoma Study Group (IRSG). Proc Amer Soc Clin Oncol (submitted), 1999.

Rodriguez-Galindo C, **Pappo AS**, Santana VM, Rao B, Kaste S, Jenkins JJ, Meyer WM, Pratt CB. Treatment of children with osteosarcoma unresponsive to standard therapy with cyclophosphamide and etoposide. Proc Am Soc Clin Oncol (submitted), 1999.

Spunt SL, Poquette CA, Hurt Y, Cain AM, Rao BN, Merchant TE, Jenkins JJ, Santana VM, Pratt CB, **Pappo AS**. Prognostic factors in children and adolescents with surgically resected non-rhabdomyosarcomatous soft tissue sarcomas (NRSTS). Proc Am Soc Clin Oncol (submitted), 1999.

Spunt SL, McCarville ME, Kun LE, Poquette CA, Brandao L, Cain AM, **Pappo AS**. Limited benefit of whole lung irradiation (WLI) in patients with Ewing's sarcoma (ES) and pulmonary metastases (PM) at diagnosis. SIOP (submitted), 1999.

Rodriguez-Galindo C, Poquette C, Tan M, Merchant T, Rao B, Pratt C, **Pappo A**. Outcome after local recurrence or local and distant recurrence in Ewing's sarcoma family of tumors (ESFTs). SIOP (submitted), 1999.

Wagner L, Rodriguez-Galindo C, Neel M, Poquette C, Cain A, Merchant T, Pappo A, Rao B. Pathologic fractures (PF) in Ewing's sarcoma (ES). SIOP (submitted), 1999.

**Pappo A**, Anderson J, Grier H, Wharam M, Breitfeld P, Hawkins D, Raney B, Womer R, Parham D, Qualman S, Crist W. Survival after relapse in children with rhabdomyosarcoma (RMS): An analysis of 609 patients (pts) enrolled on IRS-III, IRS-IV pilot (IVp) or IRS-IV. A report from the Intergroup Rhabdomyosarcoma Study Group (IRSG). Proc Amer Soc Clin Oncol 1999 (submitted)

Rodriguez-Galindo C, **Pappo AS**, Santana VM, Rao B, Kaste S, Jenkins JJ, Meyer WM, Pratt CB. Treatment of children with osteosarcoma unresponsive to standard therapy with cyclophosphamide and etoposide. Proc Amer Soc Clin Oncol 1999 submitted

Spunt SL, Poquette CA, Hurt Y, Cain AM, Rao BN, Merchant TE, Jenkins JJ, Santana VM, Pratt CB, **Pappo AS**. Prognostic factors in children and adolescents with surgically resected non-rhabdomyosarcomatous soft tissue sarcomas (NRSTS). Proc Amer Soc Clin Oncol 1999 submitted.

Spunt SL, McCarville ME, Kun LE, Poquette CA, Brandao L, Cain AM, **Pappo AS**. Limited benefit of whole lung irradiation (WLI) in patients with Ewing's sarcoma (ES) and pulmonary metastases (PM) at diagnosis. Submitted SIOF, 1999.

Rodriguez-Galindo C, Poquette C, Tan M, Merchant T, Rao B, Pratt C, Pappo A. Outcome after local recurrence or local and distant recurrence in Ewing's sarcoma family of tumors (ESFTs). Submitted SIOF, 1999.

Wagner L, Rodriguez-Galindo C, Neel M, Poquette C, Cain A, Merchant T, **Pappo A**, Rao B. Pathologic fractures (PF) in Ewing's sarcoma (ES). Submitted SIOF, 1999.

**Pappo A**, Anderson J, Qualman S, Donaldson S, Crist W. Second malignant neoplasms (SNM) in IRSG-IV: A preliminary report from the Intergroup Rhabdomyosarcoma Study Group. Submitted to ASCO 2000.

Hawkins D, Anderson J, Paidas C, Wharam M, Qualman S, Pappo A, Baker S, Crist W. Cure is the expectation for children/adolescents with middle ear (ME) rhabdomyosarcoma (RMS) treated with contemporary therapy. Submitted to ASCO 2000.

Smith L, Anderson J, Qualman S, Crist C, Paidas C, Teot L, Pappo A, Link M, Grier H, Wiener G, Breneman J, Raney R, Mauer H, Donaldson S. Clinical features, outcome, and patterns of relapse in patients with Group II rhabdomyosarcoma (RMS): A report from the Intergroup Rhabdomyosarcoma Study Group (IRSG). Submitted ASCO 2000.

Walterhouse D, Pappo A, Baker S, Parham D, Anderson J, Donaldson S, Paidas C, Womer R, Crist W. Rhabdomyosarcoma of the parotid region: A report of the Intergroup Rhabdomyosarcoma Study (IRS) Group Studies I-IV. Submitted ASCO 2000.

Pappo A, Devidas M, Jenkins J, Marcus R, Gebhardt M, Pratt C, Grier H Vincristine (V), Ifosfamide (I), Doxorubicin (D) and G-CSF (G) for pediatric unresected or metastatic non-rhabdomyosarcomatous soft tissue sarcomas: A Pediatric Oncology Group study (POG). ASCO 2001.

Hill DA, Riedley SE, Yeoh AEJ, Shurtleff SA, Patel DH, Williams WK, Pappo AS, Downing JR. Global expression profiling in childhood neuroblastoma reveals molecular signatures that correlate with prognosis and relapse. Soc Pediatr Pathol 2001.

Smithey BE, Pappo AS, Hill DA. C-kit expression in pediatric solid tumors: An immunohistochemical survey. Soc Pediatr Pathol 2001

Pappo A, Lyden E, Breitfeld P, Houghton P, Parham D, Donaldson S, Meyer W, and Crist W. Irinotecan (CPT-11) is active against pediatric rhabdomyosarcoma (RMS): A Phase II window trial from the Soft Tissue Sarcoma Committee (STS) of the Children's Oncology Group (COG) ASCO 2002.

Williams BA, Williams K, Doyle J, Greenberg M, Pappo AS, Malkin D. A Retrospective Review of Patients With Metastatic Rhabdomyosarcoma (RMS) Treated At The Hospital For Sick Children (HSC) Between 1989-1999. ASPHO 2002.

Okcu MF, Treuner J, Mattke A, Pappo A, Ferrari A, Munsell M, Ozkan A, Casanova M, Raney B. Synovial sarcoma of childhood and adolescence: multicenter multivariate analysis of outcome of 220 patients. ASCO 21:391a, (abstr 1560), 2002.

Pappo AS, Lyden E, Breitfeld PP, Houghton P, Parham D, Donaldson SS, Meyer W, Crist W. Irinotecan (CPT-11) is active against pediatric rhabdomyosarcoma (RMS): a phase II window trial from the Soft Tissue Sarcoma Committee (STS) of the Children's Oncology Group (COG). ASCO 21:393a, (abstr 1570), 2002.

Pappo A, Ries L, Herzog C, Bleyer A. Malignant melanoma in the first three decades of life: A report from the U.S. Surveillance, Epidemiology and End Results (SEER) Program. ASCO 23:721, (abstr 7557), 2004.

Price V, Zielenska M, Smith C, Shilton-Macneill S, Malkin D, Pappo A. Clinical and molecular characteristics of pediatric gastrointestinal stromal tumors (GISTs). ASCO 23:805, (abstr 8537), 2004.

Bondy M, Bernstein ML, Pappo A, Schultz KR, Krailo M, Fouladi M, Hill DA, Heinrich M, Blaney S, Adamson PC, B.C. Phase 2 Trial of imatinib mesylate (IM) for treatment of recurrent or refractory pediatric solid tumors: A Children's Oncology Group study. ASCO 23(16S):805s, (abstr 8520), 2005.

Pappo AS, Lyden E, Breitfeld LP, Donaldson SS, Anderson J, Qualman S, Wiener E, Crews K, Houghton P, Meyer W. Vincristine (V) and Irinotecan (CPT): A highly active combination in metastatic rhabdomyosarcoma. A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group (STSCOG). ASCO 23(16S):803s, (abstr 8509), 2005. Spelman AR, Okcu MF, Bondy M, Pappo A. Incidence of pediatric melanoma in Texas: A report from the Texas Cancer Registry, 1995-2003. ASCO 25(18S):489s, (abstr 8564), 2007.

Pappo A, Krailo M, Chen Z, Reaman G. The Rare Tumor Initiative of the Children's Oncology Group: Lessons Learned in the First 6 Years and Their Effect on Future Plans. ASCO 2009.

Goldberg J, Demetri GD, Choy E, Rosen L, Pappo A, Dubois S, Geller J, Chai F, Ferrari D, Wagner AJ. Preliminary results from a phase II study of ARQ 197 in patients with microphthalmia transcription factor family (MiT)-associated tumors. J Clin Oncol 27:15s (suppl; abstr 10502), 2009.

Patel S, Pappo A, Crowley J, Reinke D, Eld, J, Ritland S, Chawla S, Staddon A, Maki R, Vassal G, Helman L. A SARC global collaborative phase II trial of R1507, a recombinant human monoclonal antibody to the insulin-like growth factor-1 receptor (IGF1R) in patients with recurrent or refractory sarcomas. J Clin Oncol 27:15s (suppl; abstr 10503), 2009.

Pappo AS, Patel S, Crowley J, Reinke DK, Staddon AP, Kuenkele K, Chawla SP, Benjamin RS, Helman LJ, Baker LH. Activity of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF1R), in patients with recurrent or refractory Ewing's sarcoma family of tumors (ESFT): Results of a phase II SARC study. J Clin Oncol 28:15a (suppl; abstr 10000), 2010.

Pappo AS, Armstrong GT, Liu W, Srivastava DK, Leisenring W, Hammond S, Stovall M, Neglia JP, Robison LL. Melanoma as a subsequent neoplasm in survivors of childhood cancer: A report from the childhood Cancer Survivor Study.

Pappo AS, Janeway K, Laquaglia M, Kim SY. Special considerations in pediatric gastrointestinal tumors. J. Surg. Oncol. 2011 Dec;104(8):928-932.

Coccia PF, Altman J, Bhatia S, Borinstein SC, Flynn J, George S, Goldsby R, Hayashi R, Huang MS, Johnson RH, Beaupin LK, Link MP, Oeffinger KC, Orr KM, Pappo AS, Reed D, Spraker HL, Thomas DA, von Mehren M, Wechsler DS, Whelan KF, Zebrack BJ, Sundar H, Shead DA. Adolescent and young adult oncology. J Natl Compr Canc Netw. 2012 Sept;10(9):1112-1150.

Walterhouse D, Pappo AS, Meza JL, Breneman JC, Hayes-Jordan AA, Parham D, Cripe TP, Meyer WH, Hawkins DS. Vincristine(V), dactinomycin (A), and lower doses of cyclophosphamide (C) with or without radiation therapy for patients with newly diagnosed low-risk embryonal Rhabdomyosarcoma (ERMS): A report from the Children's Oncology Group (COG). J Clin Oncol 30, (suppl; abstr 9509), 2012.

Flaherty LE, Moon J, Atkins MB, Tuthill R, Thompson JA, Vetto JT, Haluska FG, Pappo AS, Sosman JA, Redman BG, Ribas A, Kirkwood JM, Sondak VK. Phase III trial of high-dose interferon alpha-2b versus cisplatin, vinblastine, DTIC plus IL-2 and interferon in patients with high-risk melanoma (SWOG S0008): An intergroup study of CALGB, COG, ECOG, and SWOG. J Clin Oncol 30 (suppl; abstr 8504), 2012.

Pappo AS. Treating Rare Cancer in Children: The Importance of Evidence. Submitted ASCO 2012.

Spunt SL, Million L, Anderson JR, Coffin CM, McCarville MD, Randall RL, Parham D, Kao SCS, Hayes-Jordan A, Wolden S, Terezakis S, Black J, Larie F, Tsan E, Speights R, Skapek SX, Meyer WH, Hawkins DS, Pappo AS. RiskBased Treatment for Non-Rhabdomyosarcoma Soft Tissue Sarcomas (NRSTS) in Patients under 30 Years of Age: Children's Oncology Group Study ARST0332. Submitted to ASCO 2014.

Bahrami A, Easton J, Mulder H, Lee S, Barnhill, Pappo AS. Analysis of TERT promoter mutations in pediatric melanoma. (abstr 132710), Submitted ASCO 2014.

Goshorn DR, Stewart E, Shelat A, Dyer MA, Bradley C, Pappo AS. Incorporating PARP inhibitors in translational studies for Ewing's sarcoma. (abstr 135062), Submitted ASCO 2014.

Federico SM, Stewart E, Bradley C, McEvoy J, Loh A, Shelat A, Zhang J, Chen X, Pappo AS, Dyer MA. Molecular analysis of solid tumors (MAST): A protocol for comprehensive preclinical evaluation of pediatric solid tumors. (abstr 133985), Submitted ASCO 2014.

Stewart E, Goshorn DR, Dyer MA, Shelat A, Bradley C, Pappo AS, Loh A. Preclinical evaluation of PARP inhibitors in combination with DNA damaging agents in a Ewing sarcoma orthotopic xenografts model. (abstr 135023), Submitted ASCO 2014.

Wahid FN, Loh A, Navid F, Pappo A, Bahrami A, McCarville MB, Shulkin B, Wu J, Sandoval JA, Davidoff, AM, Rao B. Results of Completion Lymph Node Dissection (CLND) in Sentinel Lymph Node-positive Pediatric Melanoma: A Single Institution Experience. Presentation International College of Surgeons Meeting, Memphis, TN, June 2014.

Bahrami A, Easton J, Mulder H, Lee S, Barnhill R, Pappo AS. Analysis of TERT promoter mutations in pediatric melanoma. Submitted to ASCO 2014.

Goshorn DR, Stewart E, Shelat A, Dyer MA, Bradley C, Pappo AS. Incorporating PARP inhibitors in translational studies for Ewing's sarcoma. Submitted to ASCO 2014.

Federico SM, Stewart E, Bradley C, McEvoy J, Loh A, Shelat A, Zhang J, Chen X, Pappo AS, Dyer MA. Molecular analysis of solid tumors (MAST): a protocol for comprehensive preclinical evaluation of pediatric solid tumors. Submitted to ASCO 2014.

Stewart E, Goshorn DR, Dyer MA, Shelat A, Bradley C, Pappo AS, Loh A. Preclinical evaluation of PARP inhibitors in combination with DNA damaging agents in a Ewing sarcoma orthotopic xenografts model. Submitted to ASCO 2014.

Bahrami A, Lee S, Fan Y, Morris J, Pappo AS, Furman WL. Molecular Mechanisms for Telomere Maintenance in Neuroblastoma. Submitted to ASCO 2015.

Bahrami A, Wu J, Dyer MA, Delattre O, Pappo AS. Loss of STAG2 Expression and Prognosis in Ewing Sarcoma Family of Tumors. Submitted to ASCO 2015.

Stewart E, Bradley C, Federico SM, Karlstrom A, Sablauer A, Pappo AS, Dyer MA. The Childhood Solid Tumor Network: a St Jude Initiative. Submitted to ASCO 2015.

Hurley C, McCarville B, Shulkin BL, Mao S, Wu J, Navid F, Daw NC, Pappo AS, Bishop MW. Comparison of 18FFDG-PET-CT and bone scintigraphy for evaluation of osseous metastases in newly diagnosed and recurrent osteosarcoma. Submitted to ASCO 2015.

Goerger B, Schulte JH, Zwaan CM, Casanova M, Fischer M, Moreno L, Trahair T, Jimenez I, Kang HJ, Pappo A, Schafer E, Weiss B, Healy ME, Li K, Lin T, Boral AL, Pearson A. Phase I Study of Ceritinib in Pediatric Patients (Pts) with Malignancies Harboring a Genetic Alteration in ALK (ALK+) – Safety, Pharmacokinetic (PK) and Efficacy Results. Submitted to ASCO 2015.

Nagasubramanian R, DuBois SG, Laetsch TW, Mascarenhas L, Smith S, Reynolds M, Cruickshank S, Donahue L, Pappo AS, Cox MC. A pediatric phase 1 study of LOXO-101, a highly selective inhibitor of the tropomyosin receptor kinase (TRK) family. Submitted to ASCO 2016. J Clin Oncol 34, 2016 (suppl; abstr TPS10583).

Furman WL, Federico SM, McCarville MB, Davidoff AM, Krasin MJ, Wu J, Brennan RC, Bishop MW, Santana VM, Bahrami A, Anthony G, Gillies SD, Sondel PM, Leung WH, Pappo AS. Improved clinical responses with the concomitant use of an anti-GD2 monoclonal antibody and chemotherapy in newly diagnosed children with high-risk

(HR) neuroblastoma (NB): Preliminary Results of a Phase II study. Submitted to ASCO 2016. J Clin Oncol 34, 2016 (suppl; abstr 10501).

Rodriguez-Galindo C, Krailo MD, Krasin MJ, McCarville MB, Hicks J, Pashankar F, Pappo AS. Treatment of Childhood Nasopharyngeal Carcinoma (cNPC) with neoadjuvant chemotherapy (NAC) and concomitant chemoradiotherapy (CCRT): Results of the Children's Oncology Group ARAR0331 study. Submitted to ASCO 2016. J Clin Oncol 34, 2016 (suppl; abstr 10513).

Seynnaeve B, Lee S, Park Y, Pappo AS, Kirkwood JM, Bahrami A. TERT promoter mutations and telomerase expression in melanoma in adolescents and young adults. Submitted to ASCO 2016. J Clin Oncol 34, 2016 (suppl; abstr 9561).

Federico SM, McCarville MB, Stewart CF, Mao S, Wu J, Davidoff AM, Furman WL, Santana VM, Pappo AS, Navid F. Phase I expansion cohort to evaluate bevacizumab, sorafenib, and low-dose cyclophosphamide in children and young adults with refractory or recurrent solid tumors. Submitted to ASCO 2016. J Clin Oncol 34, 2016 (suppl; abstr 10519).

Federico SM, Chen X, Easton J, Wu J, Mao S, Liu Y, Naranjo A, Pappo AS, Hogarty MD, Dyer MA. Association of age at diagnosis and stage of disease with ATRX mutations in neuroblastoma. Submitted to ASCO 2016. J Clin Oncol 34, 2016 (suppl; abstr 10525).

Rodriguez-Galindo C, Pappo AS, Krailo MD, Pashankar F, Caran EM, Hicks J, McCarville MB, Weldon CB, Malkin D, Zambetti G, de Oliveira-Filho AC, LaQuaglia MP, Mastellaro MJ, Ribeiro RC. Treatment of Childhood Adrenocortical Carcinoma (ACC) with surgery plus retroperitoneal lymph node dissection (RPLND) and multiagent chemotherapy: Results of the Children's Oncology Group ARAR0332 protocol. Submitted to ASCO 2016. J Clin Oncol 34, 2016 (suppl; abstr 10515).

Geoerger B, Fox E, Pappo AS, Oren MY, Marshall LV, Heath K, Diede SJ, Ebbinghaus S, Park JR; Roussy G, France V. Phase 1/2 study of pembrolizumab (pembro) in children with advanced melanoma or a PD-L1–positive (PD-L1+) advanced, relapsed, or refractory solid tumor or lymphoma (KEYNOTE-051). Submitted to ASCO 2016. J Clin Oncol 34, 2016 (suppl; abstr TPS10585).

Stewart E, Honnell V, Ocarz M, Blankenship K, Dapper J, Shelat A, Pappo AS, Dyer MA, Freeman B. Targeting the cell cycle for cancer therapy in rhabdomyosarcoma. Submitted to ASCO 2017.

Pappo AS, Bergeron C, Gore L, Sender LS, Dunkel IJ, Herzog CE, Brochez L, Cruz O, Nysom K, Berghorn E, Simsek B, Shen J, Geoerger B. Phase II study of ipilimumab (IPI) in children and adolescents with unresectable stage III or IV malignant melanoma (MEL). Submitted ASCO 2017. J Clin Oncol 35, 2017 (suppl; abstr e21006)

Stewart E, Goshorn DR, Dyer MA, Shelat A, Bradley C, Pappo AS, Loh A. Preclinical evaluation of PARP inhibitors in combination with DNA damaging agents in a Ewing sarcoma orthotopic xenografts model. Submitted to ASCO 2017.

Geoerger B, Kang HJ, Yalon-Oren M, Marshall LV, Vezina C, Pappo AS, Laetsch TW, Petrilli AS, Handgretinger R, Toporski J, Glade-Bender J, Nicholls W, Fox E, DuBois SG, Macy M, Cohn SL, Pathiraja K, Diede SJ, Ebbinghaus S, Pinto NR; Roussy G. Phase 1/2 KEYNOTE-051 study of pembrolizumab (pembro) in pediatric patients (pts) with advanced melanoma or a PD-L1+ advanced, relapsed or refractory solid tumor or lymphoma. Submitted to ASCO 2017.

Laetsch TW, DuBois SG, Nagasubramanian R, Turpin B, Mascarenhas L, Federman N, Reynolds M, Smith S, Cruickshank S, Cox MC, Pappo AS, Hawkins DS. A pediatric phase 1 study of larotrectinib, a highly selective inhibitor of the tropomyosin receptor kinase (TRK) family. Submitted to ASCO 2017.

Federico SM, Stewart E, Coleman JL, Bishop MW, Santana VM, Lam C, Hawkins D, Wu J, Mao S, Goshorn DR, Pappo AS, Dyer MA. Phase I study of talazoparib and irinotecan in children and young adults with recurrent/refractory solid tumors. Submitted to ASCO 2017.

Federman N, Albert CM, Turpin B, Mascarenhas L, Nagasubramanian R, Geoerger B, Casanova M, Gallego S,

Chisholm J, Van Tilburg CM, Shukla NN, Spunt SL, Cox MC, Hawkins DS, Pappo AS, Bielack SS, Doz FP, Bisogno G, Laetsch TW, DuBois SG, Larotrectinib SCOUT Investigators. Phase 1/2 study of the selective TRK inhibitor larotrectinib in pediatric patients with cancer. Submitted to ASCO 2017.

Furman WL, Shulkin BL, Federico SM, McCarville MB, Davidoff AM, Krasin MJ, Wu J, Brennan RC, Bishop MW, Helmig SE, Navid F, Santana VM, Anthony G, Hank JA, Gillies SD, Sondel PM, Leung WH, Pappo AS. Early response rates and Curie scores at end of induction: An update from a Phase II study of an anti-GD2 monoclonal antibody (mAb) with chemotherapy (CT) in newly diagnosed patients (pts) with high-risk (HR) neuroblastoma (NB). Submitted to ASCO 2017.

Hyman DM, Laetsch TW, Kumar S, DuBois SG, Farago AF, Pappo AS, Demetri GD, El-Deiry WS, Lassen UN, Dowlati A, Brose MS, Boni V, Turpin B, Nagasubramanian R, Cruickshank S, Cox MC, Ku NC, Hawkins DS, Hong, DS, Drilon AE. The efficacy of larotrectinib (LOXO-101), a selective tropomyosin receptor kinase (TRK) inhibitor, in adult and pediatric TRK fusion cancers. Submitted to ASCO 2017. J Clin Oncol 35, 2017 (suppl; abstr LBA2501)

### **Presentations (since 2010: local, regional, national, and international)**

**Pappo A.** Rare Tumors in Children: Challenges and Opportunities. Tumor Board, St Jude Children's Research Hospital, Memphis, TN. July 2010.

**Pappo A.** Solid Tumor Program Clinical Update. Development Therapeutics for Solid Malignancies (DTSM), St Jude Children's Research Hospital, Memphis, TN. January 2011.

**Pappo A.** Research opportunities in Rare Childhood Cancers: Melanoma and GIST as Potential Models. St Jude Cancer and Prevention Control Seminar, Memphis, TN. March 2011.

**Pappo A.** Pediatric Melanoma. Webinar Quebec University Hospital. May 2011.

**Pappo A.** Melanoma as a subsequent neoplasm in cancer survivors, Platform presentation. ASCO Annual Conference, Chicago, IL. June 2011.

**Pappo A.** Rare Tumors in Children. Tumor Board, St Jude Children's Research Hospital, Memphis, TN. July 2011.

**Pappo A.** Multidisciplinary Management of GIST, Southern Oncology Association of Practices (SOAP) Conference, St. Louis, MO. October 2011.

**Pappo A.** Rhabdomyosarcoma. Chemotherapy Foundation Symposium XXIX, New York, NY. November 2011.

**Pappo A, Bahrami A.** Basic Concepts in the Management of Pediatric Melanoma. Webinar ASPHO. December 2011.

**Pappo A.** The Challenge of Rare Cancers in Children. Peds Hem/Onc Grand Rounds Speaker, UT Southwestern Medical Center, Dallas, TX. January 2012.

**Pappo A.** New drugs for pediatric sarcomas: The rise and fall of three promising agents. Development Therapeutics for Solid Malignancies (DTSM), St Jude Children's Research Hospital, Memphis, TN. May 2012.

**Pappo A.** Treating rare cancers in children: The importance of evidence, Educational Session, ASCO (American Society of Clinical Oncology) Annual Meeting, Chicago, IL. June 2012.

**Pappo A.** Treating Rare Cancer in Children. Tumor Board, St Jude Children's Research Hospital, Memphis, TN. July 2012.

**Pappo A.** Rare Cancers in Children: Opportunities and Challenges. Chard Lecture Grand Rounds, Seattle, WA, November 1, 2012.



**Pappo A.** The Challenge of Rare Cancers in Children. Chemotherapy Foundation Symposium XXX. New York, NY, November 6, 2012.

**Pappo A.** DPLM Symposium (Speaker), Pediatric and SDH deficient GIST. Toronto, Ontario. June 2013.

**Pappo A,** Bahrami A. Genetic Profiles of Pediatric Cutaneous Melanoma. Developmental Biology and Solid Tumor Program (DBSTP), St Jude Children's Research Hospital, Memphis, TN. February 2013.

**Pappo A.** Pediatric and SDH deficient Gist: An up and coming disease. Pediatric GIST Clinic, NIH, Bethesda, MD. June 2013.

**Pappo A.** Tumor Board Presentation, Rare Cancer in Children: An Overview. Tumor Board, St Jude Children's Research Hospital, Memphis, TN. August 2013.

**Pappo A.** Chemotherapy Foundation Symposium XXXI (Speaker). Osteosarcoma: Biology and Therapy, New York, NY. November 2013.

**Pappo A.** Fellows Rounds (Speaker), Osteosarcoma, St Jude Children's Research Hospital. January 2014.

**Pappo A.** Developmental Biology and Solid Tumor Program (DBSTP) Speaker, "REBX: A Protocol for Prospectively Collecting and Banking Fresh Tumor Tissue in Children and Adolescents with Solid Malignancies." Developmental Biology and Solid Tumor Program (DBSTP), St Jude Children's Research Hospital, Memphis, TN. January 2014.

**Pappo A.** Promesa Presentation, Speaker, St Jude Children's Research Hospital, Memphis TN. January 2014.

**Pappo AS.** The BRAF pathway: An emerging therapeutic target in Childhood Cancer. Pediatric melanoma, ASCO Educational Session June 2014.

**Pappo A.** Rare Tumors: Improving Outcomes in the Modern Era. ASCO (American Society of Clinical Oncology) Annual Conference, Chicago, IL. May 2015.

**Pappo A.** What Rare Childhood Cancers Can Teach Us? Grand Rounds Speaker, Rainbow Babies & Children's Hospital, Cleveland, OH. September 2015.

**Pappo A.** Pediatric Solid Tumors: Challenges and Opportunities. Grand Rounds with Dr. Dyer, Cook Children's Hospital, Fort Worth, TX. October 15, 2015.

**Pappo A.** Pediatric Cancer Genome Project. Grand Rounds, Charlotte Affiliate. Charlotte, NC. October 28-29, 2015.

**Pappo A.** NCI Pediatrics Provocative Questions Workshop. St. Jude Children's Research Hospital, Memphis, TN. November 2015.

**Pappo A.** Visiting Professor Lecture, Rare Cancers in Children. Children's Mercy Hospital, Kansas City, MO. April 25-26, 2016.

**Pappo A.** Melanoma in Children and Adolescents: A multidisciplinary Workshop and Case Discussion on Diagnosis Therapy and Follow-up. ASPHO 29th Annual Meeting. Minneapolis, MN, May 11-14, 2016.

**Pappo A.** Rare cancers, CTRSTC (Clinical Translational Research in Solid Tumors Conference –Speaker), St Jude Children's Research Hospital. July 2016.

**Pappo A.** Pediatric melanoma, Fellows Rounds (Speaker), St Jude Children's Research Hospital. January 2017.

**Pappo A.** Pediatric melanoma. Pediatric Grand Rounds, UT Health Science Center at San Antonio, TX. May 18, 2018.

**Pappo A.** Rare tumors in children. Greehey Distinguished Lecture. San Antonio, TX. May 18, 2018.

## **A. Oral Presentations**

**Pappo A.** Challenges and opportunities for incorporating molecular targeted therapy in pediatric sarcoma trials. ASPHO, Montreal. April 2010.

**Pappo A.** Phase II trial of R1507 in ESFT, Platform presentation. ASCO Annual Conference, Chicago, IL. June 2010.

**Pappo A.** Soft tissue sarcomas in the AYA population. Texas Adolescent and Young Adult Oncology Conference, San Antonio, TX. October 2010.

**Pappo A.** NCCN 16th Annual Conference: Clinical Practice Guidelines & Quality Cancer Care, Hollywood, FL. March 2011.

**Pappo A.** Oral abstract discussant. Ewing sarcoma: Is there a role for high dose chemotherapy? ASCO 2016 (American Society of Clinical Oncology) Annual Conference, Chicago, IL. June 2016.

**Pappo A.** Oral poster discussant. Rare Tumours. SIOP 2016 (International Society of Paediatric Oncology) Annual Congress, Dublin, Ireland. October 20-21, 2016.

## **B. Poster Presentations**

**Pappo A.** Activity of R1507 in non-Ewing sarcoma tumors. CTOS Annual Meeting, Paris, France. November 2010.